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ABSTRACT 
Alzheimer’s disease (AD) is the most common form of dementia affecting more than 
50 million people worldwide today and is characterised by progressive cognitive 
decline. One of the earliest events in AD, which is also closely related to neuronal loss 
and the degree of dementia, is synaptic degeneration. The degree of dementia has been 
found to correlate better with synaptic loss compared to other neuropathological 
changes, such as plaques and tangles. Synaptic proteins are therefore highly suitable 
as biomarkers for AD, possibly also for diagnosis, even at early stages. 
The aim of this thesis was to characterise the postsynaptic protein neurogranin (Ng) in 
cerebrospinal fluid (CSF), plasma, and brain tissue, develop methods for quantification 
of Ng as well as to test the hypothesis that Ng in CSF and plasma is a possible 
biomarker for AD. Using hybrid-immunoaffinity mass spectrometry (HI-MS) 15 
endogenous Ng peptides in CSF, 16 in plasma and 39 in brain tissue were identified. 
Based on the peptide profiles, it seems that there are most likely two separate pools of 
Ng; one derived from the central nervous system (CNS) and one from the periphery. 
In particular, Ng peptides ending at amino acid 76 were specifically detected in the 
CNS but not in the periphery, and the levels of the specific peptide Ng48-76 was 
increased in CSF from sporadic AD (sAD) patients in two separate cohorts. While 
plasma Ng was not significantly altered in sAD compared to controls, CSF Ng 
quantified by immunoassays was increased in sAD in multiple independent cohorts. In 
addition, CSF Ng was also increased in patients with mild cognitive impairment that 
progressed to AD, thus showing that Ng can be used to detect AD even at early stages. 
Furthermore, when comparing CSF Ng across eight different neurodegenerative 
diseases, including Parkinson’s disease, frontotemporal dementia, and sAD, CSF Ng 
was only increased in patients having AD pathology. Increased CSF Ng in sAD was 
also demonstrated in autopsy-confirmed cases. Finally, Ng in both CSF and brain 
tissue was found to correlate very well with the degree of neuropathological changes, 
thus showing that there is a close relationship between Ng and disease-specific changes 
in AD. 
Examination of Ng in brain tissue revealed that the concentrations of several Ng 
peptides were increased in relationship to full-length Ng, in both sAD and familial AD 
compared to controls and individuals that are cognitively intact but have developed 
AD pathology. These data indicated a shift from full-length Ng to Ng peptides in AD, 
demonstrating that the formation of Ng peptides in brain tissue might be connected to 
AD-related synaptic degeneration leading to cognitive decline. The increase of 
peptides in brain tissue is most likely what causes the mirrored increase of CSF Ng as 
well. 
In conclusion, the work included in this thesis has shown that the postsynaptic protein 
Ng is a CSF biomarker for AD, even at early stages, and that it also is specific for sAD 
compared to other major neurodegenerative diseases. The increase of Ng in sAD CSF 
is most likely caused by elevated levels of Ng peptides being produced in the brain as 
a result of synaptic degeneration. Thus, Ng is indeed a new, and useful, item in the AD 
biomarker toolbox. 
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SAMMANFATTNING PÅ SVENSKA 
Alzheimers sjukdom (AD) är den vanligaste typen av demens och har blivit en av vår 
tids största folksjukdomar med över 100 000 drabbade enbart i Sverige. Då de kliniska 
symptom och minnestester som idag används för att ställa diagnos delvis är för 
”trubbiga” för att identifiera patienter med lindrig minnesstörning, vilka ännu inte har 
fullt utvecklad AD, eller individer med mycket tidig AD, är behovet av mer exakta 
metoder stort.   
Ett av de tidigaste fynden i AD är skador på och förlust av nervceller och synapser, 
vilket leder till minnesstörningar. Synapser är kontaktpunkterna mellan nervceller, där 
minnen skapas, överförs och lagras, och dessa känsliga kopplingar är mycket sårbara 
för de förändringar som sker vid AD. Synapserna är till stor del uppbyggda av unika 
proteiner som bara finns just där och många av dem går att mäta i ryggvätska (även 
kallad cerebrospinalvätska eller likvor), vilken är en färglös vätska som omger hjärnan 
och bl.a. skyddar den från stötar samt transporterar bort restprodukter. Eftersom 
ryggvätska är i direktkontakt med hjärnan lämpar den sig mycket väl för att identifiera 
samt mäta relevanta sjukdomsmarkörer. Störd synapsfunktion är som tidigare nämnts 
en av de tidigaste förändringarna vid utvecklingen av AD och tidigare studier har visat 
att neurogranin, ett protein som uttrycks specifikt i synapserna, är ett nyckelprotein för 
synapsernas funktion och har en mycket viktig roll i bildningen samt lagringen av 
minnen. Fram tills nu har det dock inte funnits några sätt att mäta synapshälsa i den 
åldrande hjärnan. 
I avhandlingen har fokus varit dels att karakterisera neurogranin i blod, ryggvätska 
samt hjärnvävnad, för att få en större förståelse för hur neurogranin påverkas av 
sjukdomsförloppet i AD, och dels att utveckla robusta metoder för att mäta 
neurogranin. Genom att analysera neurogranin i ryggvätska från individer med AD, 
tidig AD, andra former av demens samt friska individer med flera olika metoder har vi 
kunnat visa att ökade koncentrationer av neurogranin i ryggvätska fungerar som en 
sjukdomsmarkör för synapshälsa samt att den är specifik för just AD, vilket är viktigt 
för att kunna utesluta andra neurodegenerativa sjukdomar. Vidare har vi också visat att 
den är användbar även vid identifiering av individer med tidig minnesstörning som 
senare utvecklar AD. Koncentrationen av neurogranin i både ryggvätska och 
hjärnvävnad visade ett starkt samband med mängden patologiska förändringar i 
hjärnan vilket indikerar att neurogranin med största sannolikhet speglar 
sjukdomsförloppet väl. 
Sammanfattningsvis visar resultaten att neurogranin i ryggvätska är en ny och mycket 
användbar sjukdomsmarkör för AD, men större studier och även uppföljningsprover 
över en längre tid behövs för att utvärdera neurogranin i större skala.
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1 INTRODUCTION 
Dementia is defined as a significant decline in one or several aspects of cognitive 
performance which has a negative impact on daily life and function1. 50 million people 
worldwide were living with dementia in 2018, and the number is expected to have 
tripled by 20502. Dementia is diagnosed based on the history of the illness and which 
cognitive domains that are affected. In addition, structural imaging of the brain, as well 
as blood tests, are often used in order to rule out non-degenerative causes such as stroke 
or tumours. As of today, there is no cure, i.e. a way to stop the neurodegenerative 
process and onset of neuropathological changes, and the medications that are available 
only treat or modify the symptoms3. 
1.1 CEREBROSPINAL FLUID 
Cerebrospinal fluid (CSF) is produced by specialised cells in the choroid plexus of the 
ventricles of the brain and circulates within the brain and spinal cord. As CSF is in 
direct contact with the central nervous system (CNS) it provides a valuable diagnostic 
window into the brain. At any given moment, the total volume of CSF in an adult is 
around 150 mL, but it is continuously reabsorbed and reproduced4. CSF has several 
functions, and apart from providing hydromechanical protection of the CNS, it also 
allows circulation of substances5 and removal of waste products6. The CNS is 
separated from the periphery, i.e. blood, by the blood-brain barrier (BBB) and the 
blood-CSF barrier (BCSFB), both of which prevent free diffusion of soluble molecules 
across them by tight junctions between the endothelial cells of CNS microvessels 
(BBB) or choroid plexus epithelial cells (BCSFB). Instead, transport of nutrients, ions, 
etc. is enabled by specialised transport proteins7. It has been shown that soluble 
extracellular forms of β-amyloid (Aβ) can be cleared from the brain by various routes8, 
including across the BBB9. Thus, there are multiple ways through which proteins from 
the CNS can end up in the periphery8. It should be noted that BBB function can be 
altered by various causes, such as traumatic brain injury10,  inflammation11, and 
neurodegenerative diseases12, 13. 
CSF can be sampled through a lumbar puncture (LP) between the L3/L4 or L4/L5 
vertebrae, and there are standardised procedures to follow with regard to certain 
aspects of the procedure14. The most common complication after an LP is post-lumbar 
puncture headache, which, although harmless, might last for several hours up to a 
week15-17. 
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1.2 BIOMARKERS 
What is a biomarker? According to the definition of the International Programme on 
Chemical Safety, led by the World Health Organization and in coordination with the 
United Nations and the International Labor Organization, a biomarker is defined as 
“any substance, structure, or process that can be measured in the body or its products 
and influence or predict the incidence of outcome or disease”18. In the human body, 
biomarkers can be measured in tissue or bodily fluids such as blood, saliva, or CSF. In 
the setting of neurodegenerative diseases, biomarkers could potentially have multiple 
uses. They can be diagnostic, i.e. used in order to make a diagnosis; they can be 
prognostic, i.e. used to determine if a person will remain at the same cognitive level or 
deteriorate; and finally they can also be predictive, i.e. used to determine who will get 
the disease or not. In addition, biomarkers may also be used for discriminating between 
different neurodegenerative diseases, as well as staging or determining the extent of 
the disease and monitoring response to a drug either in the clinic or during 
pharmaceutical trials19. 
1.3 NEURODEGENERATIVE DISEASES 
Neurodegenerative disease is an umbrella term used to describe diseases that result 
from progressive neurodegeneration, i.e. loss of neurons, and include both dementia 
and movement disorders. The presentation of the disease or syndrome varies 
depending on the kind of neurodegenerative process, what type of cell(s), and what 
area(s) of the brain that is affected. To further complicate matters, different 
combinations of affected areas and types of neuropathological changes might give a 
heterogeneous presentation of symptoms between patients. Neurodegenerative 
diseases are often categorised and classified either based on the type and location of 
neuropathological change, presentation of clinical symptoms, or a combination of 
both20. 
Something that many neurodegenerative diseases have in common is protein 
aggregation which most likely is the end stage of a series of molecular processes. These 
aggregates may be toxic to neurons thus ultimately causing cell death21. Sometimes, 
mutations in specific genes make proteins more prone to aggregate, and such mutations 
can result in hereditary variants which are often called familial versions of the disease 
in question22. 
There are many challenging aspects to neurodegenerative diseases, for instance, that 
most of them have a fairly long presymptomatic phase, during which 
neuropathological changes accumulate but do not yet cause any clinical symptoms, 
meaning that when clinical symptoms do arise, the disease is most likely already fairly 
advanced20, 23. Moreover, making a clinical diagnosis can be quite difficult as it is 
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relatively common with atypical presentations of symptoms or that symptoms correlate 
poorly with the degree of neuropathological changes. In addition, even though post-
mortem neuropathological examination is the gold standard for many diseases24-26, 
meaning it is the only way to make a definitive diagnosis, there is a high incidence of 
multiple pathologies, so-called comorbidities27-29. 
1.3.1 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) was first described in 1906 by the German psychiatrist and 
pathologist Alois Alzheimer and was later named after him. He described a single case, 
characterised by memory disturbances and neuropathological findings of extracellular 
miliary bodies and dense bundles of neurofibrils. Today, these are all recognised to be 
hallmarks of AD30. Representing approximately 60-80% of all dementia cases, AD is 
the most common cause of dementia31 with a prevalence of around 5% in the 
population of 60 years and above32. The incidence increases with age and roughly 
doubles every five years after the age of 65 years33. AD is characterised by an insidious 
onset and progressive decline of cognitive functions. The most common clinical 
presentation is impaired episodic memory, but other common symptoms include 
changes in personality, judgement, and behaviour, as well as aphasia, apraxia, and 
agnosia30. There are also cases which have an atypical presentation, with language, 
visual or executive problems that are more pronounced and earlier than memory 
deficits. These are discussed under posterior cortical atrophy (PCA). AD is 
characterised by a long pre-clinical phase, and neurodegeneration is estimated to start 
20-30 years before the onset of clinical symptoms34, during which pathological 
changes accumulate. As a result, by the time the symptoms are pronounced enough to 
make the patient seek medical attention, and a diagnosis is made, the 
neurodegenerative processes will have caused considerable and irreversible damage 
manifesting as cognitive decline. As treatments are most likely to have maximum 
impact and efficiency at earlier stages when the brain is relatively intact, early 
diagnosis is of utmost importance16, 35. As of today, there is no cure or a way to slow 
neurodegeneration in AD, and the only approved medications are aimed at treating or 
modifying the symptoms. For instance, acetylcholinesterase inhibitors and N-methyl-
D-aspartate (NMDA) agonists such as mementin are used to treat cognitive symptoms 
but do not affect the underlying disease process36. 
1.3.1.1 Pathology 
The neuropathological hallmarks of AD are neuronal loss in certain areas of the brain, 
with early affected areas comprising the medial temporal lobe (hippocampus and 
entorhinal cortex), in addition to intraneuronal neurofibrillary tangles (NFTs) and 
extracellular neuritic plaques. The NFTs consists of aggregated, and sometimes 
truncated, hyperphosphorylated tau protein while the plaques are composed of Aβ 
peptides30, mainly ending at amino acid (aa) 42, i.e. AβX-4237. 
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Plaques follow a general path of spreading from cortical to subcortical regions38, while 
NFTs spread in an opposite pattern thus starting in subcortical and ending in the 
cortical regions39, 40. In the more advanced stages of AD, neuroanatomical distribution 
of NFTs correlates both with the cognitive domains that are affected as well as areas 
of neuronal death41. However, it is rare that only one type of neuropathological change 
is present in an elderly individual. Studies show that irrespective of clinical symptoms 
and diagnosis, up to around 70% of cases display multiple pathologies, such as AD 
pathology, Lewy body pathology, vascular pathologies, TAR DNA binding-protein 43 
(TDP-43) proteinopathy, and hippocampal sclerosis, and comorbidity of pathological 
changes has been shown to increase with age29. Almost 40% of dementia cases that are 
not clinically diagnosed as AD display enough AD neuropathology to fulfil the criteria 
for an AD diagnosis42. It is also worth to note that AD pathology is quite common in 
non-demented older individuals39, with studies estimating 30-40% of cognitively 
healthy elderly individuals classified as positive for AD pathological changes upon 
autopsy43-45. From here on, such individuals are referred to as cognitively-unaffected 
amyloid positive (CU-AP). However, even though CU-AP individuals have plaques, 
the composition of these might differ compared to plaques in AD brains46, indicating 
that the exact mechanisms leading to neuropathological changes might differ. 
There are scoring systems for determining the extent, i.e. presence, distribution, and 
frequency, of plaques and NFTs. Thal phases (0-5) are used to determine the spread of 
the amyloid plaques throughout the brain38, while Braak stages (0-VI) determine the 
distribution of tau pathology47. In addition, there is the Consortium to Establish a 
Registry for AD (CERAD) neuritic plaque score which is used to classify AD 
neuropathology into four groups (no or negligible – high level)48. The Braak, Thal, and 
CERAD scoring can also be combined into an ABC score, which thus incorporates all 
of the described neuropathological aspects48. 
1.3.1.2 Heritability and Risk Factors 
Most AD cases have no known cause and are called sporadic (sAD) but autosomal 
dominant mutations in genes related to the metabolism of amyloid precursor protein 
(APP), i.e. PSEN1 and PSEN2, are the major underlying cause of the hereditary form 
called familial AD (fAD) which accounts for around 1%, or less, of all cases. APP is 
the precursor of Aβ peptides and is cleaved by presenilin 1 and 2, encoded by PSEN1 
and PSEN2, which are both included in the γ-secretase complex49, 50. fAD can also be 
caused by mutations in APP which affect how the secretases, e.g., γ-secretase, process 
APP49 and today a total of more than 300 mutations in PSEN1, PSEN2 and APP have 
been identified51. While sAD usually presents after the age of 65, fAD generally has a 
much earlier disease onset and a more rapid progression. The pathogenic mutations in 
APP are so called missense mutations, i.e. leading to the coding of a different aa, and 
the mutations are most often located in the Aβ-encoding gene sequence, often near 
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protease cleavage sites which alter the proteolytic processing of APP. The effects of 
APP mutations include increased overall production of Aβ peptides, an increase of the 
Aβ1-42/Aβ1-40 ratio, increased secretion of Aβ1-42 and Aβ1-40, and increased 
oligomerisation, to mention a few. A detailed list can be found at 
https://www.alzforum.org/mutations/app52. The vast majority of PSEN mutations are 
also missense mutations which among other things results in an increase in the Aβ1-
42/Aβ1-40 ratio50. There are also examples of protective mutations53. 
Even though no single genetic cause of sAD has been identified there are genetic risk 
factors associated with sAD, the most prominent one being APOE, which encodes for 
apolipoprotein E (apoE). APOE has three alleles, ε2, ε3, and ε4, where ε2 appears to 
be protective, ε3 neutral, and ε4 harmful. The most common allele is ε3, followed by 
ε4, and ε254. ε2 exerts its protective effect by decreasing the overall risk of developing 
sAD as well as delaying onset55. In contrast, ε4 lowers age of onset and increases risk 
in a dose-dependent manner. Individuals that are heterozygous or homozygous for ε4 
have an increased risk, three and 15 times more likely, respectively, to develop sAD 
compared to an individual without a copy of the ε4 allele50.  The mechanism by which 
APOE modulates risk might be connected to clearance of Aβ peptides from the brain, 
which appears to differ between the isoforms56. It has also been shown that ε4 carriers 
exhibit lowered cerebral glucose metabolism and have greater atrophy of certain areas 
of the brain, including the hippocampus57. 
1.3.1.3 The Amyloid Cascade Hypothesis 
The underlying cause of AD is still not known, but the most widely accepted suggested 
pathological pathway is called the “amyloid cascade hypothesis”. The amyloid cascade 
hypothesis was introduced in 1992, and identifies increased production and 
aggregation of Aβ1-42 as the primary driving mechanism of the disease, leading to the 
formation of plaques and NFTs and ultimately neuronal death and dementia58. The Aβ 
peptides are generated by proteolytic processing of APP by β- and γ-secretase59  and 
there are many Aβ peptides present in both human CSF60 and brain tissue37. Evidence 
supporting the amyloid cascade hypothesis include for instance that mutations in genes 
related to APP metabolism cause fAD49-51 and that an extra copy of APP, which occurs 
in Down’s syndrome, leads to the formation of plaques even in adolescents with AD 
pathology increasing with age, presumably due to overproduction of Aβ61. In many 
ways, due to the popularity of the amyloid cascade hypothesis, principally all disease-
modifying drugs in clinical trials have been aimed at altering the concentrations of Aβ 
in the brain in different ways. However, so far all have failed, and no new drugs for 
AD have been approved since 200362 leading to that the amyloid cascade hypothesis 
has been extensively criticized63, 64, mainly because of the failures to modify the course 
of AD by targeting Aβ. 
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While most of the AD field acknowledge that Aβ is central to the disease, not all agree 
that Aβ peptides are the driving force behind the disease. There are a few alternative 
hypotheses for the underlying cause of AD, two of which focus on inflammation65 and 
oxidative stress66. It has been known for a long time that there is a neuroinflammatory 
component to AD, but the inflammation has most often been assumed to be a 
consequence of, or response to, the pathophysiological changes67. The inflammatory 
processes within the brain are driven by microglia, and the degree of inflammation 
increases with disease progression65. Moreover, strong associations between AD and 
mutations in several genes related to the immune system have been identified in 
addition to reports of increases in inflammatory cytokines, chemokines, and other 
molecules related to inflammation67. The other major alternative hypothesis, oxidative 
stress, also has a lot of supporting evidence, including increased DNA and protein 
oxidation in AD as well as studies showing that Aβ peptides are capable of generating 
free radicals66. Oxidative damage occurs early in the disease process, preceding a high 
plaque load and has been liked to abnormal phosphorylation of tau and mitochondrial 
dysfunction68. 
1.3.1.4 Diagnosis 
The first diagnostic criteria for AD were presented in 1984 by the Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA). However, since no biomarkers were 
available at the time, these criteria were for probable, possible, or definite dementia 
due to AD based on clinical symptoms and exclusion of other dementias69. Probable 
AD was defined as dementia with progressive impairment of memory and cognitive 
function in the absence of other disease causing the symptoms, while definitive AD 
could only be diagnosed by neuropathology upon autopsy69. The specificity and 
sensitivity for these criteria have been reported to 80% and 70% respectively70.  The 
American Psychiatric Association released the fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) in 1994 (revised in 2000), in which 
the AD criteria were comparable to the NINCDS-ADRDA71, 72. According to DSM-
IV, a dementia diagnosis requires the loss of two or more of the following cognitive 
domains: memory, language, calculation, orientation, or judgement. As both fluid and 
imaging biomarkers emerged and the reported changes were shown to be consistent in 
AD, the International Working Group (IWG) for New Research Criteria for the 
Diagnosis of AD proposed new criteria which were presented in 2007. The IWG 
criteria were based on identifying the core symptoms for progressive memory 
impairment in combination with one or more positive biomarkers; either imaging 
(hippocampal volumetric magnetic resonance imaging (MRI), or positron emission 
topography (PET)), or fluid (CSF Aβ1-42, total tau (t-tau), and phosphorylated tau (p-
tau)). In addition, these criteria provided tools for the diagnosis not only of AD 
dementia but also for the different stages of the disease, including prodromal AD, also 
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called mild cognitive impairment (MCI)73. Revised criteria based on the 1984 
NINCDS-ADRDA were presented in 2011 by the National Institute on Aging-
Alzheimer’s Association (NIA-AA) in which biomarkers, as well as MCI, was 
introduced into the NIA-AA framework74.  
MCI is a clinical syndrome characterised by an evident decline in memory or other 
cognitive abilities, that does not impair day-to-day functioning, and does not meet 
criteria for dementia defined by DSM-IV75. In addition, MCI subjects have prominent 
amnestic symptoms, above what is considered to be normal for age, that indicate a pre-
stage of AD75. As with AD, the pathological changes in MCI might not exclusively be 
AD-related but rather a mixture of different pathologies76, 77. One study reported 88% 
of MCI subjects to have AD neuropathological hallmarks78, thus indicating that MCI 
indeed is a pre-stage of AD in a majority of cases. Other commonly underlying causes 
are vascular pathology and depression79. The prevalence of MCI differs between 
studies, but is somewhere between 3-19% after the age of 65, and while some remain 
cognitively stable over time, around half progress to dementia within 5 years80. As 
mentioned, MCI due to AD is generally characterised by amnesia75, but there is also 
non-amnestic MCI which is mostly caused by other neurodegenerative diseases such 
as frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) or vascular 
dementia80. 
IWG-2 is a recent update of the IWG criteria, and include only the core CSF AD 
biomarkers and amyloid PET, but not hippocampal volumetric MRI, as supporting 
evidence of AD pathology. In the IWG-2 criteria, biomarkers are now included as 
research criteria for the diagnosis of AD, meaning that the disease can be diagnosed 
using these supportive biomarkers. In short, one of the three following biomarkers need 
to be positive: low CSF Aβ1-42 and high t-tau or p-tau; PET scan indicating the presence 
of plaques; an autosomal dominant mutation81. In 2018, NIA-AA presented updated 
guidelines for researchers in order to incorporate the current understanding of the 
disease as defined by biology rather than clinical symptoms. According to the 2018 
criteria, an AD diagnosis is defined by the pathological appearance of plaques and 
tangles and that these can be documented in vivo using biomarkers26. This biological 
approach is in stark contrast to the other criteria which put a lot of weight on symptoms 
and signs, such as cognitive decline, that rather are clinical manifestations of the 
neurodegeneration and pathological changes. 
There are a number of different tests aimed at assessing various aspects of cognitive 
performance which can be used when evaluating suspected dementia in a patient33. The 
most widely used screening test for evaluating cognition is called Mini-Mental Status 
Examination (MMSE) and was first described by Paul R. McHugh and colleagues in 
1975, but it is still extensively used. The MMSE test is comprised of 30 points 
distributed on 19 items measuring orientation, memory, concentration, language, and 
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praxis82. Generally accepted cut off scores are cognitively intact (27-30), mild AD (21-
26) and moderate AD (12-20)83. However, it is not possible, or at the very least very 
difficult, to discriminate between AD and other dementias solely based on clinical 
history coupled with cognitive and neuropsychiatric tests, which is why biomarkers 
are essential. 
1.3.1.5 Biomarkers 
In AD, there are currently three core biomarkers that are measured in CSF and used 
for diagnosis as well as inclusion criteria in clinical trials: Aβ1-42, p-tau, and t-tau16, 84 
(Figure 1). AD and MCI due to AD are characterised by lowered CSF concentrations 
of Aβ1-42, as this peptide is retained in the plaques, combined with increased 
concentrations of both t-tau and p-tau, which reflect axonal damage and tangle 
formation, respectively16, 23, 35, 84, 85. The core AD biomarkers show high sensitivity and 
specificity for AD, around 85-90%85. However, recent studies have highlighted the fact 
that there is much to gain from utilising the Aβ1-42/Aβ1-40 ratio compared to Aβ1-42 alone 
in order to increase diagnostic accuracy 86-88. By adding the Aβ1-42/Aβ1-40 or Aβ1-42/Aβ1-
38 ratio, there is very little overlap between AD and healthy controls89. The hypothesis 
is that using the ratio normalises for high- and low-producers of Aβ90. 
Figure 1. Core cerebrospinal fluid biomarkers in Alzheimer’s disease. A neuron 
containing NFTs with adjacent plaques. In AD, CSF Aβ1-42, which reflects plaques, is 
decreased while CSF t-tau and p-tau, reflecting axonal damage and NFTs respectively, 
are increased. The postsynaptic protein neurogranin might be used in order to evaluate 
dendritic and/or postsynaptic dysfunction and degeneration. 
Apart from fluid biomarkers in CSF, considerable efforts are being put into identifying 
plasma biomarkers, which would be very useful since plasma is much more easily 
accessible. One of the most widely pursued is plasma Aβ, and recent mass 
spectrometry (MS)-based assays have shown that the plasma Aβ1-42/Aβ1-40 ratio has a 
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good diagnostic ability91, 92. However, more studies need to be performed before it can 
be implemented as an accurate biomarker. 
In addition to the fluid biomarkers, there are also imaging techniques which allow 
monitoring of pathophysiological changes in the brain of living patients. Structural 
MRI can be used in order to determine the degree of atrophy. Typically, the entorhinal 
cortex is the earliest area affected by atrophy, followed shortly by the hippocampus 
and amygdala. PET scans are based on assessing the retention of radioactive ligands 
in the brain. The metabolism of the brain can be assessed using the radioligand 2-[18F]-
fluoro-2-deoxy-D-glucose (18F-FDG), i.e. FDG-PET, and AD is characterised by 
hypometabolism of certain areas including the hippocampus. The metabolic 
deficiencies gradually worsen with disease progression93. There are also PET tracers 
that bind to Aβ plaques, the most widely evaluated being Pittsburgh compound B 
(PiB)94, i.e. PiB-PET, but there are now several amyloid tracers available95. A high 
inverse correlation has been shown between PiB-PET and the CSF Aβ1-42/Aβ1-40 ratio 
thus indicating that the two methods both reflect the amyloid burden of the brain96. 
Recently, tau tracers capable of visualising NFTs have also been developed and are 
reported to associate well with both brain atrophy and cognitive decline97 in addition 
to being able to discriminate between AD and other neurodegenerative diseases98. 
Dysfunction and loss of synapses are directly linked to cognitive symptoms even at 
early stages of the disease and are thought to precede neuronal loss99. It has also been 
shown that the severity of dementia is more closely associated with the extent of 
synaptic loss than plaques and NFTs100-103. Thus, synaptic proteins could potentially 
fill a gap in the diagnostic panel that is used today, not only as early biomarkers for 
AD, but they might also be used to monitor disease progression and evaluating 
prospective disease-modifying therapies. Recently, several novel synaptic markers 
have been investigated including synaptosomal nerve-associated protein 25 (SNAP-
25)104, synaptotagmin105, synaptic vesicle protein 2A (SV2A)106, growth-associated 
protein 43 (GAP-43)107, and neurogranin (Ng)108, the latter of which will be discussed 
in detail in this thesis. 
1.3.2 AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease in which patients 
display both upper and lower neuron signs109. ALS is one of the major 
neurodegenerative diseases along with AD and Parkinson's disease (PD), and 
descriptions date back at least until the early 19th century,  but the connection between 
symptoms and underlying neurological problems was first described in 1874 by Jean-
Martin Charcot110. The incidence of ALS is around 2 per 100,000 persons/year with 
males having a slightly higher incidence than females 109, 111, at least in the sporadic 
variant. There is no cure for the disease112 and cause of death is most commonly 
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respiratory failure, which usually occurs 2-5 years after the onset of first symptoms, 
but survival time have been known to vary between a few months up to several 
decades113, 114. However, there is one disease-modifying drug that has shown moderate 
promising results in terms of extending survival time mainly by delaying the need for 
artificial respiration115. 
1.3.2.1 Pathology 
Neuropathological changes associated with ALS include loss of myelinated axons in 
the lateral and anterior columns of the spinal cord, small round or oval shaped 
eosinophilic inclusions in motor neurons of the spinal cord and brain stem, called 
Bunina bodies, and ubiquitinated inclusions containing TDP-43 in the cytoplasm of 
anterior horn cells116. 
1.3.2.2 Heritability and Risk Factors 
There are two variants of ALS, one sporadic and one familial, of which the latter 
accounts for approximately 5-10% of the cases. Familial ALS can be caused by 
mutations in SOD1 (20 %), TARDBP (2-5%)117, FUS, and the most recently discovered 
hexanucleotide repeats (GGGGCC) in C9ORF72, which encodes for superoxide 
dismutase, TDP-43, fused in sarcoma (FUS), and  chromosome 9 open reading frame 
72 respectively, to mention a few118. C9ORF72 has been shown to be the most common 
mutation in both the sporadic (6%) and familial form (40%) of ALS119. In addition, 
C9ORF72 has also been linked to autosomal-dominant FTD120, and 20-50% of all ALS 
patients fulfil consensus criteria for probable or definite FTD121. Age of onset is around 
60 years for sporadic ALS while familial ALS manifests earlier with a mean onset of 
around 50 years of age122. Most cases of familial ALS show an autosomal dominant 
pattern of inheritance, but some cases of autosomal recessive inheritance have been 
reported as well123, 124. 
1.3.2.3 Diagnosis 
The El Escorial criteria for diagnosis of ALS were established in 1994125, with the 
purpose of standardising the diagnosis, and have since then been revised twice126, 127. 
The El Escorial criteria stage ALS into probable, possible, and definitive diagnosis, 
although in the latest revision it was stated that the former categories of probable and 
definite ALS should be replaced by a new and validated staging system as a diagnosis 
can be made simply if the criteria for possible ALS are fulfilled127. According to the 
El Escorial criteria, the diagnosis of ALS requires the presence of signs of both upper 
and lower motor neuron degeneration as well as progressive spread of symptoms 
within a region or into other regions. Such signs must also be in the absence of 
electrophysiological evidence of other signs of disease that might explain the 
degeneration of upper and lower motor neurons and neuroimaging evidence of disease 
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processes that might explain clinical manifestations and electrophysiological results125. 
Neuronal loss in the lower motor system results in denervation of muscles and 
symptoms such as cramps and muscle weakness while degeneration of upper motor 
neurons presents as spasticity and fasciculations128. There is also a second set of criteria 
called the “Awaji-Shima” criteria in which electromyography, used to evaluate 
electrical activity produced by skeletal muscles, is added to the El Escorial criteria129. 
1.3.2.4 Biomarkers 
There are several potential CSF and blood biomarkers for ALS, including 
neurofilaments, TDP-43130, and cytokines131, with CSF neurofilament light (NfL) 
showing especially high promise132. 
1.3.3 CORTICOBASAL DEGENERATION 
Corticobasal degeneration (CBD) is a rare, progressive neurodegenerative disorder 
which can only be diagnosed upon autopsy133. The disease is called corticobasal 
syndrome (CBS) when diagnosed by clinical criteria. It was first described in 1968 as 
corticodentatonigral degeneration with neuronal achromasia134, and the term CBD was 
introduced in 1989135. The symptoms of the first described cases emphasized 
progressive movement abnormalities including slowing of voluntary movements as 
well as presence of involuntary movements. Neuropathological findings included 
frontoparietal atrophy with neuronal loss, gliosis, and pigment loss in the substantia 
nigra134. However, clinicopathologic studies have revealed that CBD can be considered 
to be an atypical parkinsonian disorder as it mainly manifests as a movement disorder 
(or at least many case series have had data biased towards movement disorders as a lot 
of cases have been identified from movement disorder clinics) with symptoms such as 
tremor and bradykinesia136, but it may also present as a cognitive disorder with 
neuropsychological impairments137. Mean age of onset is around 64 years24 and mean 
disease duration is less than 7 years133. There is no cure, but the individual symptoms 
can be treated136. 
1.3.3.1 Pathology 
Neuropathological findings in CBD are frontoparietal atrophy, accumulation of NFTs 
consisting of the insoluble four-repeat isoform of tau in neurons, astrocytes, and 
oligodendroglial cells, ballooned neurons, substantia nigra and focal cortical neuronal 
loss136, 138, 139. CBD pathology is very closely related to progressive supranuclear palsy 
(PSP), which also is classified as an atypical parkinsonian disorder, and the most 
reliable way to discriminate between them is by looking at what type of astrocytic tau-
containing inclusion that is present; plaques in CBD vs. tufted in PSP140. In addition, 
the ballooned neurons which are characteristic for CBD are not present in PSP139. To 
make matters more complicated, CBD is very heterogenic as the underlying pathology 
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can be AD, FTD, Pick disease, PSP, or PCA, to mention a few138, 141, 142. Since 
pathological findings associated with CBD also have been found in patients with 
FTD143 and the FTD subgroup primary progressive aphasia (PPA)143, 144 it has been 
proposed to call the clinical presentation CBS in order to distinguish it from the 
neuropathological entity of CBD143, which can only be definitely diagnosed upon 
autopsy24. 
1.3.3.2 Heritability and Risk Factors 
Although most cases are sporadic, there have been reported cases of familial CBD as 
well. However these are quite rare and such cases seems to be associated with 
mutations in GRN, encoding for progranulin, mutations and frontotemporal lobe 
degeneration (FTLD) with TDP-43 immunoreactive inclusions (FTLD-TDP) rather 
than tau24. 
1.3.3.3 Diagnosis 
CBD is a complex neurodegenerative disorder and diagnosis is often complicated. 
Based on clinical phenotypes of autopsy-confirmed CBD cases, diagnostic criteria for 
CBD have identified four phenotypes; CBS (possible and probable), frontal 
behavioural-spatial syndrome (FBS), non-fluent/agrammatic variant of primary 
progressive aphasia (naPPA), and progressive supranuclear palsy syndrome (PSPS). 
Probable CBS have an asymmetrical presentation of at least two motor symptoms 
including limb rigidity or akinesia, limb dystonia or alien limb phenomena24. 
1.3.3.4 Biomarkers 
Imaging to evaluate patterns of atrophy may be promising and could also be used in 
order to exclude other conditions with similar clinical presentations. CSF biomarkers 
of CBD have not yet been sufficiently studied24. 
1.3.4 DEMENTIA WITH LEWY BODIES 
DLB is the second most common type of dementia in elderly people, accounting for 
10-20% of all cases145. Lewy bodies were first described by Friedrich Heinrich Lewy 
in 1912146 and received their name in 1917147, but it was not until much later that the 
association with dementia was recognised and the term DLB was introduced148, 149. The 
prevalence is around 0.4% in people aged 65 or above, and symptom onset usually 
occurs between 50 and 70 years of age150. There is no cure, but most symptoms can be 
improved upon treatment151. 
1.3.4.1 Pathology 
In DLB, the primary pathological finding is intraneuronal Lewy bodies, comprised of 
inclusions consisting of aggregated α-synuclein152 and ubiquitin153, in many areas of 
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the brain including the neocortex, forebrain, and brainstem. There are also Lewy 
neurites, which correspond to normal neurites that contain filaments similar to those 
found in Lewy bodies154, and thus also contain α-synuclein155. However, Lewy bodies 
and Lewy neurites are not exclusive to DLB but are also the main pathological 
component of multiple system atrophy 156, 157 and PD158, 159. As all of these diseases 
have aggregated α-synuclein in Lewy bodies as a common pathology, they are 
sometimes referred to as α-synucleinopathies157. The presence of plaques and tangles, 
i.e. AD pathology, in DLB can modify the clinical symptoms, for instance resulting in 
a lowered rate of both parkinsonism and visual hallucinations. Thus, comorbidity of 
AD pathology in DLB makes it more challenging to distinguish AD and DLB 
clinically154. 
1.3.4.2 Heritability and Risk Factors 
Most cases of DLB are sporadic, but there have also been reports of occurrences in 
families160. Also, several loci161, 162, including APOE ε4163, have been associated with 
increased risk of developing DLB. 
1.3.4.3 Diagnosis 
The newly revised criteria for clinical diagnosis of possible and probable DLB state 
that “dementia, defined as a progressive cognitive decline of sufficient magnitude to 
interfere with normal social or occupational functions, or with usual daily activities, is 
an essential requirement for DLB diagnosis”. Core clinical features are defined as 
fluctuation; visual hallucinations; parkinsonism; rapid eye movement (REM) sleep 
behaviour disorder. There are many supportive clinical features such as severe 
sensitivity to antipsychotic agents, postural instability, transient episodes of 
unresponsiveness, and hypersomnia. A diagnosis of possible DLB can be made if one 
core clinical feature is present, with or without indicative biomarkers (see below), or 
if at least one indicative biomarker is present in the absence of core clinical features. 
Probable DLB can be diagnosed when at least two core clinical features are present 
with or without the presence of any indicative biomarkers, or only one core clinical 
feature but with at least one indicative biomarker151. 
1.3.4.4 Biomarkers 
Biomarkers are not yet required for the diagnosis of DLB, but, as mentioned above, 
they are included as an indication of the disease. Indicative biomarkers include reduced 
dopamine transporter uptake in basal ganglia, demonstrated by single-photon emission 
computed tomography (SPECT) or PET, and polysomnographic confirmation of REM 
sleep without atonia, but there are also several supportive biomarkers.  Certain specific 
electroencephalography (EEG) patterns is an example of a supportive biomarker151. 
Imaging, such as MRI, to determine grade and localisation of atrophy164, and CSF α-
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synuclein might be useful in order to differentiate DLB from AD165. Two other 
promising biomarkers are plasma concentrations of epidermal growth factor and 
apolipoprotein A1, but these need to be confirmed in larger studies164. 
1.3.5 FRONTOTEMPORAL DEMENTIA 
FTD is the clinical neurodegenerative syndrome of the neuropathological entity FTLD. 
FTLD displays a complex pathological pattern of neurodegeneration166 and molecular 
neuropathology167 resulting in progressive deficits in language, behaviour, and 
executive functions168. Arnold Pick published the first description of FTD in 1892 of 
a patient that had aphasia, lobar atrophy, and presenile dementia169. FTD is the most 
common form of early-onset dementia and overall the third most common type of 
dementia, after AD and DLB168. Age of onset is typically around 65 years of age, and 
the prevalence is 15-22 per 100,000 individuals170. Based on clinical presentation, FTD 
can be further divided into either a behavioural variant FTD (bvFTD), which is the 
most common variant, or language disorders of primary progressive aphasia (PPA). In 
addition, PPA has three clinically distinct language disorder subgroups of logopenic 
variant PPA (lvPPA), non-fluent variant PPA (nfvPPA), and semantic variant PPA 
(svPPA)171. Current medication strategies for treatment of FTD symptoms are mostly 
based on increasing or replacing neurotransmitters and modifying behavioural 
symptoms172. 
1.3.5.1 Pathology 
Neuropathological changes in FTLD are in most cases characterised by relatively 
selective atrophy of the frontal and temporal lobes. There are several distinct molecular 
pathologies included in FTLD, which are classified according to the major constituents 
of the intracellular protein inclusions into FTLD-tau, FTLD-TDP, and FTLD-FUS. 
The most common form is FTLD-tau, where hyperphosphorylated tau forms 
inclusions, which is found in 40-50% of all cases. Apart from FTLD, Pick disease, 
CBD, and PSP are also characterised by the same inclusions as in FTLD-tau. FTLD-
TDP is found in roughly half of FTLD and can be further divided into the three major 
subtypes of FTLD-TDP: type A, B, and C, which all have distinct patterns of 
cytoplasmic or intranuclear pathology and cortical association. Finally, FTLD-FUS 
accounts for about 10% of all FTLD cases168. It is worth to note that FTLD-FUS is 
sometimes grouped with pathological inclusions of FUS, Ewing's sarcoma (EWS), and 
TATA‐binding protein‐associated factor 15 (TAF15), and in these cases this 
pathologically distinct group is called FTLD with FUS/EWS/TAF15 (FTLD-FET)167. 
1.3.5.2 Heritability and Risk Factors 
The heritability of the disease differ between FTD variants, and up to 50% of the cases 
report a positive family history, but 10-27% of all FTD cases have been found to 
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display an autosomal dominant mode of inheritance173. Mutations in VCP, encoding 
for valosin-containing protein, CHMP2B, which encodes for charged multivesicular 
body protein 2B, TARDBP, and FUS are found in less than 5% of familial FTD 
cases173. It was long known that familial FTD was linked to chromosome 9 and in 2011 
researchers managed to identify a hexanucleotide (GGGGCC) repeat in C9ORF72 
causing autosomal dominant FTD120. Mutations in C9ORF72, MAPT, encoding for tau, 
and GRN together account for around 60% of the familial cases174. 
1.3.5.3 Diagnosis 
The first diagnostic criteria for bvFTD were presented in 1994 by the Lund and 
Manchester groups175. The criteria were updated in 1998 and included recognition of 
semantic dementia and progressive non-fluent aphasia (now called nfvPPA) as well as 
introducing both core and supportive diagnostic features176. Autopsy studies have 
shown that the 1998 diagnostic criteria correctly classify 80-90% of bvFTD cases, 
although they lacked sensitivity in early phases of the disease173. An additional set of 
revised criteria for bvFTD were published in 2007 where neuroimaging and genetics 
were added, and the role of supportive behavioural features was given more 
importance177. In the most recent bvFTD diagnosis criteria possible bvFTD require 
three of the following symptoms: disinhibition; apathy; hyperorality and/or executive 
deficits; compulsive behaviour or loss of empathy. For probable bvFTD at least three 
of the described symptoms need to be displayed, in addition to significant functional 
decline and that imaging results must be consistent with bvFTD, e.g. MRI showing 
frontal and/or temporal lobe atrophy. bvFTD with definitive FTLD pathology can be 
diagnosed either by histopathological evidence, i.e. upon autopsy, or by the presence 
of a known pathogenic mutation178. There are also criteria for the three variants of 
PPA, in which a patient first needs to meet basic PPA criteria which include insidious 
onset and gradual progression of impairment in language such as object naming or 
syntax. Everyday life should not be impaired except for activities related to language. 
Classification into one of the PPA variants may occur on a clinical, imaging or 
definitive pathological level. For a diagnosis supported by imaging, the localisation of 
neuroimaging changes should be consistent with those previously associated with each 
variant of PPA. To summarise the clinical core criteria, lvPPA is characterised by 
impairments in word retrieval such as names and repetition of phrases, nfvPPA 
displays agrammatism and/or apraxia of speech, while svPPA is identified by impaired 
word comprehension and/or confrontation naming171. Guidelines for clinical staging 
and disease progression in FTD and its variants have also been proposed179. 
1.3.5.4 Biomarkers 
Currently, there are no fluid biomarkers used in FTD diagnosis but the core AD 
biomarkers, i.e. CSF Aβ1-42, p-tau, and t-tau, can be used to differentiate FTD patients 
from AD patients. However, AD-like CSF profiles are also found in lvPPA178 patients, 
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which often have underlying AD pathology180. NfL is one of the most promising 
biomarkers for FTD and increased concentrations compared to control individuals 
have been reported in both CSF and blood181. Both volumetric MRI, which measures 
grey matter atrophy, and FDG-PET, used to visualise and quantify alterations in brain 
metabolism, are very useful in FTD181. In FTD, volumetric MRI shows regional grey 
matter atrophy in certain areas including the frontal and temporal lobes and FDG-PET 
reveals hypometabolism181. Neuroimaging is included in the diagnostic criteria for 
probable bvFTD178 as well as classification of PPA variant171. 
1.3.6 PARKINSON’S DISEASE 
PD is the second most common neurodegenerative disease and is characterised by loss 
of dopamine-secreting, i.e. dopaminergic, neurons in the substantia nigra which cause 
dopamine deficiency. The prevalence is approximately 1% in individuals of 60 years 
of age or above182. PD was first described by James Parkinson in 1817 who referred to 
it as shaking palsy or paralysis agitans, and observed symptoms included tremors and 
a forward bent posture183. Treatments for motor symptoms consist mainly of drugs that 
enhance the concentrations of intracerebral dopamine or stimulate dopamine receptors 
and include levodopa and dopamine agonists. Another option to treat moderate-to-
severe PD is deep brain stimulation, where a neurostimulator, which sends electrical 
impulses, is implanted to stimulate either the subthalamic nucleus or globus pallidus 
internus184. Studies have shown that deep brain stimulation can have positive effects 
on both motor and non-motor features of PD185. A potential problem when it comes to 
both treatment and research is that by the time a patient starts to display symptoms, a 
loss of 70-80% dopaminergic neurons may already have occurred186. 
1.3.6.1 Pathology 
The main pathological finding in PD is intraneuronal Lewy bodies, containing 
aggregated α-synuclein, which appear in six suggested stages spreading from the 
medulla oblongata, through the midbrain and mesocortex into the neocortex158. 
1.3.6.2 Heritability and Risk Factors 
As with many other neurodegenerative diseases, there are both sporadic and familial 
forms of PD, with familial PD being estimated to account for less than 10% of all 
cases. At least five genes have been shown to have a clear link to PD including SNCA, 
also called PARK1 and PRKN, also called PARK2, which encodes α-synuclein and 
parkin respectively, as well as LRRK2, encoding for leucine-rich repeat 
serine/threonine-protein kinase 2. Mutations in SNCA and LRRK2 have been identified 
in families showing autosomal dominant inheritance while PRKN mutations have been 
liked to autosomal recessive PD. LRRK2 mutations are the most common cause of both 
sporadic and autosomal dominant PD187. 
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1.3.6.3 Diagnosis 
PD diagnostic criteria developed by the National Institute of Neurological Disorders 
and Stroke (NINDS) includes staging into possible, probable, and definite PD. Criteria 
for possible PD include at least two of four PD motor characteristics, i.e. resting 
tremor, rigidity, asymmetric onset, or bradykinesia, of which one must be rest tremor 
or bradykinesia. Also, no symptoms suggestive of alternative diagnosis should be 
present, and the patient should have a substantial response to a dopamine receptor 
agonist or levodopa, which is a precursor to dopamine that is converted to dopamine 
once it has entered the CNS. In order to meet the criteria for probable PD at least three 
PD characteristics should be present for at least three years with no features suggestive 
of an alternative diagnosis and a substantial response to levodopa or dopamine receptor 
agonist. Definite PD can only be diagnosed upon autopsy as all criteria for probable 
PD should be met with the addition of histopathological confirmation of diagnosis, 
meaning neuronal loss and Lewy bodies within the substantia nigra188. Non-motor 
symptoms include for instance cognitive impairment and olfactory dysfunction189, and 
can be present at prodromal stages190. 
1.3.6.4 Biomarkers 
There are currently no biomarkers used in the diagnosis of PD. However, biomarkers 
capable of diagnosing PD in the prodromal stage would be of high value both for the 
development of treatments and accurate identification of patient groups191. Potential 
future biomarkers include CSF α-synuclein192, 193 and CSF protein deglycase DJ-1192, 
which is a chaperone that inhibits α-synuclein aggregation194. 
1.3.7 POSTERIOR CORTICAL ATROPHY 
PCA, which describes a progressive neurodegenerative syndrome, was first introduced 
by Benson et al. in 1988 after observation of five patients that had progressive 
dementia preceded by disorders of higher visual functions as well as predominant 
parieto-occipital atrophy195. However, others disagreed and argued that it was merely 
an unusual presentation of AD196. In later years it has been shown that the majority of 
autopsied brains from patients with PCA have AD pathology in the form of plaques 
and tangles197. In light of these findings, PCA is also commonly referred to as atypical 
AD198, 199. What sets PCA apart from AD is that age of onset tends to be much earlier 
than AD, with symptom onset reported from mid-50s to early 60s200, 201, and some 
clinical features that are not typical of AD202, such as fewer memory difficulties and 
greater insight of illness200. The effectiveness of pharmacological treatments for AD is 
not known in PCA203, but most PCA patients require treatments with 
antidepressants200. 
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1.3.7.1 Pathology 
Pathological studies have shown that the underlying neuropathological cause of PCA 
is AD, but some cases are attributable to other causes such as DLB or CBD, meaning 
the presence of either Lewy bodies or astroglial inclusions of tau, respectively203. 
Using neuroimaging to localise and quantify patterns of atrophy it has been shown that 
patients with PCA have significant reductions of grey matter in several areas, 
especially in the occipital and parietal lobes, compared to controls204, 205. Also, greater 
right parietal and less left medial temporal and hippocampal atrophy was found in PCA 
compared to AD. Several studies have also reported asymmetric atrophy patterns in 
PCA with atrophy more pronounced in the right hemisphere203. Compared to a typical 
case of AD, most neuropathological examinations of PCA have revealed increased 
numbers of plaques and tangles in the occipital areas as well as fewer lesions in the 
prefrontal cortex206, 207. Nevertheless, considerable overlap between AD and PCA have 
also been reported in several regions, including inferior parietal lobe and precuneus208 
and CSF biomarkers seem to be very similar between the two diseases209-212. 
1.3.7.2 Heritability and Risk Factors 
PCA has so far not been connected with any autosomal dominant mutations203. As in 
AD, APOE seems to be associated with PCA, but the associated risk may be smaller 
compared to AD. Other genes suggested to be connected to PCA are CR1 and ABCA7, 
which encodes for complement receptor type 1 and ATP-binding cassette sub-family 
A member 7, respectively213. 
1.3.7.3 Diagnosis 
Clinical manifestations of PCA include insidious onset and gradual progression of 
symptoms, prominent visuoperceptual and visuospatial impairments without 
significant impairment of actual vision, indication of complex visual disorders, such 
as visual field defects, but relatively intact memory and insight. However, once 
neurodegeneration spreads to anterior cortical regions patients may also experience 
symptoms similar to AD, such as memory loss and deficits in cognition and language 
203, 214, 215. In PCA, working memory and anterograde memory tends to be impaired 
while episodic memory is still intact, which is also in contrast to AD, as AD patients 
typically have reduced episodic memory203, 216. 
Two sets of diagnostic criteria of PCA have been proposed with suggested core 
features of: gradual progression and insidious onset; presentation of visual deficits 
without any ocular disease; relatively unaffected episodic memory, verbal fluency, and 
personal insight; presence of symptoms including dyspraxia and apraxia; absence of 
stroke or tumour. Supportive features include onset before the age of 65 and 
neuroimaging indicating PCA200, 217. The consensus classification proposes several 
 19 
 
classification levels in order to define the disease and an extensive definition of 
suggested core criteria as well as staging into prodromal/suspected/possible PCA, 
PCA, and advanced PCA. In prodromal/suspected/possible PCA, the patient displays 
subtle deficits in posterior cortical functions, but symptoms are too mild or few to fulfil 
the core criteria. PCA is defined as fulfilment of the core criteria, and advanced PCA 
also fulfils the core criteria with the addition that the progression of neurodegeneration 
has led to impairment of other cognitive functions such as episodic memory, language, 
and executive functions27. 
1.3.7.4 Biomarkers 
The core AD biomarkers show very similar results in AD and PCA209-212, which, 
together with the fact that most PCA cases have underlying AD pathology197, is why 
PCA is considered to be an atypical variant of AD203. 
1.3.8 PROGRESSIVE SUPRANUCLEAR PALSY 
PSP, also called Richardson’s syndrome, was first described in 1964 by John Steele 
and collegues218 and is the most common form of atypical parkinsonism219. The 
prevalence is 5 per 100,000 individuals220 and age of onset is around 63 years of age221. 
PSP is a clinical syndrome characterised by supranuclear palsy, postural instability 
resulting in frequent falls, and mild dementia. Since the symptomatic picture often is 
complex, the treatment strategy is diverse but often include levodopa, although the 
benefits are limited222. 
1.3.8.1 Pathology 
Neuropathological changes include accumulation of tau in NFTs and neuropil threads 
mainly in pallidum, subthalamic nucleus, red nucleus, substantia nigra, pontine 
tegmentum, striatum, oculomotor nucleus, medulla, and dentate nucleus. However, 
these pathological changes can also be found in other diseases. The most specific 
pathological features of PSP are star-shaped astrocytic tufts and NFTs that can be seen 
with light microscopy and strongly immunostain against tau223. 
1.3.8.2 Heritability and Risk Factors 
PSP is considered to be a sporadic disease. Although rare variants caused by mutations 
in MAPT have been identified, these do not share identical aetiology with the sporadic 
cases. Mutations in LRRK2 and PRKN have been observed in autopsy-confirmed cases, 
but it is not clear how these mutations may influence PSP224. 
1.3.8.3 Diagnosis 
The most widely used criteria for ante-mortem diagnosis of PSP are the National 
Institute of Neurological Disorders and Stroke and Society for PSP (NINDS‐SPSP) 
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clinical diagnosis criteria published in 1996225. The 1996 NINDS-SPSP diagnostic 
criteria have very good specificity for both possible and probable PSP, with around 
80-93% and 95-100% respectively, as confirmed by autopsy224. However, these 
criteria failed to diagnose cases that were not typical or that were early in the disease 
course. Therefore, revised guidelines aimed to optimise early, sensitive, and specific 
clinical diagnosis were recently presented. The revised criteria for possible or probable 
PSP contain mandatory inclusion criteria of: sporadic occurrence; age 40 or more at 
onset of first PSP symptoms; gradual progression of PSP symptoms. There are also 
mandatory exclusion criteria as well as context-dependent exclusion criteria. 
Symptoms are divided into four functional domains: ocular motor dysfunction; 
postural inability; akinesia; cognitive dysfunction. Each functional domain also has 
three levels of certainty. In addition, there are also supportive features such as 
levodopa-resistance and photophobia224. 
1.3.8.4 Biomarkers 
CSF NfL might be useful for diagnosis as it is increased in PSP compared to PD and 
DLB226. In a clinical trial, where several biomarkers were monitored longitudinally, 
CSF NfL was the only biomarker that changed over time, and it also correlated with 
changes in several clinical symptoms, indicating that it could be used to monitor 
progression of the disease227. NfL can also be detected in plasma, and PSP plasma NfL 
is increased compared to controls and PD. In addition, baseline concentrations of 
plasma NfL can be used to predict disease progression226. 
1.4 SYNAPSES 
Synapses are the functional units of the brain, communicating signals between 
neurons. A human brain is estimated to have approximately 100 billion neurons with 
an estimated average of 7000 synapses each, and the adult human brain is thought to 
have 100 to 500 trillion synapses228. Synapses are composed of a presynaptic (axonal) 
terminal that is connected with a postsynaptic dendritic domain called the dendritic 
spine. Neurotransmitters are released by the transmitting synapse in response to an 
influx of Ca2+ caused by an action potential. When the neurotransmitters are received 
by receptors on the dendrite, it results either in a changed transmembrane potential, 
which is either inhibitory or excitatory, or a modulated production of messenger 
molecules which can amplify both excitatory and inhibitory signals. Excitatory 
transmembrane potentials trigger an influx of positive ions, i.e. K+, Na+ and Ca2+, 
resulting in a slightly positive overall charge of the cell, while inhibitory potentials 
result in a slightly negative net charge229. 
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Research has shown that synapses are not static, but in fact plastic. Synaptic plasticity 
is the basis for most models of memory and learning.  Long-term potentiation (LTP), 
and the converse process long-term depression (LTD), is carefully controlled activity-
dependent modification of synapses resulting in a long-lasting increase or decrease of 
synaptic efficiency230. LTP causes an influx of Ca2+ which subsequently results in the 
activation of calcium-calmodulin-dependent protein kinase II (CaMKII) by 
calmodulin. Ca2+ alters the affinity of calmodulin for its target proteins thereby 
increasing the probability of it to activate CaMKII. However, the availability of 
calmodulin is regulated by Ng. Upon activation, CaMKII interacts with 
neurotransmitter receptors at the synapse. CaMKII also have a role in enlargement and 
strengthening of synapses in later stages of LTP231. It has been shown that both Aβ 
dimers isolated from AD brain tissue232 and naturally secreted Aβ oligomers233 are 
capable of inhibiting LTP as well as enhancing LTD234.  It has been proposed that the 
association between AD and LTP is mediated by Aβ peptides that reduce LTP and/or 
promote LTD, which leads to delays in basal synaptic transmission ultimately resulting 
in synaptic loss and neurodegeneration235. As already mentioned, synaptic loss is a 
central event in AD236, but it also plays a part in many other neurodegenerative diseases 
such as PD and multiple sclerosis237. 
1.5 NEUROGRANIN 
Ng is a 78 aa long postsynaptic protein that was first identified in bovine brain tissue 
in the late 1980s238. Although Ng is considered to be neuron-specific, it is also 
expressed in low levels in lung tissue, bone marrow, and the spleen. Also, platelets 
have been shown to express high levels of Ng239. In the brain, Ng is present in dendritic 
spines of neurons within associative cortical areas, including the hippocampus, 
amygdala, and cerebral cortex239, 240. Studies on the human brain using in situ 
hybridisation have shown that there is a selective translocation of Ng mRNA to 
dendrites, and that such translocation is impaired in the cortex of sAD patients241. Ng 
is an important unit for LTP function through its interaction with calmodulin. During 
resting state, Ng binds to calmodulin via an IQ motif (aa 33–46) which is well 
conserved among other calmodulin-binding proteins. Upon Ca2+ entry in response to 
neurotransmitters, Ng is phosphorylated at S36 by protein kinase C (PKC) and is 
thereby inhibited from binding calmodulin242 (Figure 2). However, the 
phosphorylation is transient243, and Ng is in this manner able to regulate the 
concentration of calmodulin by responding to intracellular concentrations of Ca2+ 
levels following neuronal excitation. Phosphorylation of Ng seems to be needed for 
efficient LTP, as mutated Ng that could not be phosphorylated resulted in significantly 
reduced LTP, most likely through sequestering of calmodulin, thus stopping it from 
activating its targets, such as CaMKII244. In mice, concentrations of both Ng protein 
and mRNA decrease with age and these changes are related to CNS dysfunction245. 
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Furthermore, reduced cognition and LTP is displayed in knockdown mouse models246. 
In contrast, upregulation of Ng expression results in improved cognition and LTP247, 
thus signifying the importance of Ng in these processes. Staining of human cortex for 
Ng shows a synaptic-like pattern248. 
 
Figure 2. The role of neurogranin in long-term potentiation. In response to the influx 
of Ca2+, Ng dissociates from calmodulin and is phosphorylated at S36 by PKC, which 
prohibits Ng from binding calmodulin. Once calmodulin no longer is bound by Ng, it 
will interact with downstream targets, such as CaMKII which results in increased LTP. 
When studying Ng in human brain tissue using semi-quantitative western blot (WB) it 
was shown that Ng levels in both the frontal cortex and hippocampus of AD were 
decreased compared to controls249. In 1999 it was shown that Ng, as well as other 
synaptic proteins, are present in human CSF250, and in 2010, a first study showed that, 
in contrast to brain tissue, the relative CSF levels of Ng are increased in AD compared 
to controls108. During the last few years, the interest of Ng as a possible biomarker for 
AD has increased. Several independent studies have shown that CSF Ng, measured by 
different immunoassays, is increased in sAD compared to controls251-255 and it is now 
a well-replicated biomarker for sAD (http://www.alzforum.org/alzbiomarker). 
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2 AIM 
2.1 GENERAL AIM 
The overall aim of the work included in this thesis is to characterise Ng in CSF, plasma, 
and brain tissue of controls and AD patients, develop methods for quantification of Ng 
and to test the hypothesis that Ng is a novel biomarker for AD. 
2.2 SPECIFIC AIMS OF EACH PAPER 
Paper I: Evaluate in-house developed monoclonal Ng antibodies and use them to 
characterise Ng in CSF and brain tissue. Furthermore, the purpose is to quantify Ng in 
CSF using both HI-MS and ELISA in order to evaluate CSF Ng as a novel biomarker 
in AD. 
Paper II: Characterise Ng in plasma and to evaluate if plasma Ng can be used as a 
novel biomarker for AD. In addition, the aim is to test the stability of CSF Ng during 
storage and investigate if the detected peptides are continuously generated in CSF and 
plasma. 
Paper III: Investigate if increased CSF Ng is specific for AD compared to other 
neurodegenerative diseases and evaluate how CSF Ng, as measured by ELISA, 
correlates with pathology in AD. 
Paper IV: Characterise endogenous Ng peptides as well as full-length Ng, including 
possible post-translational modifications (PTMs), in brain tissue in addition to 
quantifying both peptide and full-length Ng in brain tissue from two regions of sAD, 
fAD, controls and CU-AP individuals.  
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3 MATERIALS AND METHODS 
3.1 SUBJECTS AND SAMPLE COLLECTION 
All subjects gave their informed consent, and recruitment, as well as sample collection, 
was performed in accordance with ethical permissions approved by regional ethical 
committees. Detailed demographics of all participants, as well as diagnosis criteria, 
can be found in the respective papers. 
De-identified CSF samples from the Clinical Neurochemistry Laboratory at the 
Sahlgrenska University Hospital, Mölndal, Sweden, was used for method 
development. 
3.1.1 CEREBROSPINAL FLUID 
In Papers I-III, CSF was collected according to standardised procedures. Briefly, 12 
mL of CSF was acquired via LP through the L3/L4 or L4/L5 interspace and collected 
in polypropylene tubes. Insoluble material was subsequently removed by 
centrifugation at 2000 × g at +4 °C for 10 min before the supernatant was transferred 
and aliquoted into new tubes. The CSF was finally stored at −80 °C.  
3.1.2 PLASMA 
Plasma, which was used in Paper II, was obtained by centrifugation of whole blood 
that had been collected in tubes coated with the anticoagulant 
ethylenediaminetetraacetic acid (EDTA) at 2500 × g at +4 °C for 10 min. The plasma 
was aliquoted in polypropylene tubes and stored at −80 °C. 
3.1.3 BRAIN TISSUE 
Brain tissue was used in Papers I and IV. One hemisphere was fixed in formalin 
solution for several weeks, followed by dissection and both histological and 
immunohistological staining. Neuropathological diagnosis and scoring were made by 
neuropathologists. The other hemisphere was flash frozen and stored at −80 °C. 
3.2 IMMUNOPRECIPITATION 
In CSF, the three most abundant proteins together constitute around 80% of the total 
protein content, making sample clean-up and/or enrichment helpful for some analyses 
as well as necessary before MS analysis256. Immunoprecipitation (IP) is a highly 
efficient way to enrich peptides and/or proteins from complex samples such as CSF, 
plasma, or tissue homogenates. IP combined with MS (IP-MS) (further on referred to 
as hybrid-immunoaffinity mass spectrometry (HI-MS)) can be used in many ways such 
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as determining PTMs, identifying protein complexes257 or characterising endogenous 
peptides from a protein60. There are several ways to perform an IP; in this thesis, the 
method was based on magnetic beads to which in-house generated anti-Ng antibodies 
were bound. Briefly, the sample is incubated with the bead-antibody complex on a 
mixer to allow binding of the protein of interest. The incubation is followed by several 
washing steps and finally elution60 (see Figure 3 for an overview). In order to minimise 
binding of unspecific proteins to the beads as well as prohibit large amounts of the Ng 
antibodies from being eluted with the sample, which can disturb MS analysis, in 
particular, MALDI analysis of full-length Ng, crosslinking can be utilised. By 
crosslinking, the antibodies are covalently bound to the beads often using either 
dimethyl pimelimidate (DMP) or bis[sulfosuccinimidyl] suberate (BS3), but the 
crosslink reaction can also decrease the efficacy of antigen binding258. Quantification 
is possible by the addition of a known concentration of one or more stable heavy 
isotope-labelled peptide(s), using for instance 15N or 13C, preferably corresponding to 
the peptide(s) one is interested in quantifying. In Paper I, IP followed by WB was used 
to show that the in-house generated monoclonal anti-Ng antibodies were able to detect 
endogenous Ng in brain tissue homogenates. HI-MS was used in Papers I, II, and IV 
in order to characterise and relatively quantify full-length and peptide Ng in CSF, 
plasma, and brain tissue. 
Figure 3. Schematic picture of immunoprecipitation of neurogranin used in this 
thesis. 
3.3 IMMUNOASSAYS 
There are many different types of immunoassays, but what they all have in common is 
that antibodies are used to detect and quantify a certain analyte. It should also be noted 
that immunoassays can be used to determine the presence of antibodies in a sample as 
well, and in those instances, an antigen is used for detection instead. Typically, an 
immunoassay involves binding of the analyte, several washing steps, binding of the 
detection antibody that is coupled to some type of detectable label followed by a 
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chemical or enzymatic reaction that allows detection and quantification. There are 
many types of labels, including radioactive isotopes, fluorogenic reporters and 
electrochemiluminescent (ECL) tags, but the most commonly used is enzymes. 
Immunoassays that are based on enzymatic reactions are called enzyme-linked 
immunosorbent assays (ELISAs). In a sandwich ELISA, two antibodies against the 
same antigen are used; one for coating the microtiter plate that is used for capturing of 
the antigen, and another for detection. A common set up in ELISA is to have the 
detection antibody conjugated to biotin and add streptavidin-conjugated horseradish 
peroxidase (HRP), followed by the addition of chromogenic substrate. It is the colour 
change following the HRP enzymatic reaction that is detected and quantified using a 
spectrophotometer, i.e. ELISA reader. In ECL, light is emitted from electrochemically 
generated intermediates that undergo a highly exergonic reaction. Luminophores, 
which are the functional groups responsible for luminescence of a compound, 
generally ruthenium complexes such as tris(bipyridine)ruthenium ([Ru (bpy)3]2+), 
emits light after excitation following electron-transfer reactions259. Some results 
indicate that ECL assays might provide increased sensitivity and broader dynamic 
range compared to conventional ELISA, and some systems also offer the possibility to 
multiplex analytes in the same assay260.  
In Papers, I, II, and III immunoassays were used to quantify Aβ1-42, p-tau, and t-tau 
using commercially available kits in order to biochemically classify patients as AD or 
control. In addition, in Papers I, III, and IV, Ng was quantified in CSF and brain tissue 
using in-house developed ELISAs based on in-house generated monoclonal anti-Ng 
antibodies. In Paper II, an in-house developed assay using in-house generated 
monoclonal anti-Ng antibodies and Meso Scale Discovery (MSD) Technology, which 
is based on ECL, was used to quantify Ng in CSF and plasma samples. 
3.4 WESTERN BLOT 
WB is a technique used for detection of specific proteins in for instance tissue samples 
or bodily fluids such as CSF. The sample can also be purified or enriched before WB 
by for instance IP. The basis for WB is gel electrophoresis which separates the proteins 
in a sample according to size. Gel electrophoresis can be performed in denaturing or 
non-denaturing, so-called native, conditions. Native gel electrophoresis can be useful 
since the activity of enzymes is kept intact. The difference between native and 
denaturing gel electrophoresis is that in native gels the proteins are separated based on 
both their molecular weight and tertiary structure, while separation during denaturing 
conditions is based only on molecular weight as the tertiary structure is destroyed. In 
WB, proteins in the sample are denatured and separated according to size during gel 
electrophoresis after which they are transferred to a membrane and detected using an 
antibody that is specific to the protein of interest. Lastly, a secondary antibody, that 
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recognises the first antibody is added and detected using for instance 
chemiluminescence based on streptavidin, biotin, and HRP, similar to the previously 
described ELISA procedure, but with a luminescent substrate instead of a chromogenic 
one. A very common set up is polyacrylamide gel electrophoresis (PAGE) combined 
with sodium dodecyl sulphate (SDS). In SDS-PAGE, the proteins are negatively 
charged by SDS and are then forced to migrate through the polyacrylamide network 
by applying a current261. Larger proteins will migrate more slowly compared to smaller 
ones, and different percentages or concentration gradients of polyacrylamide can be 
used depending on the size of the protein(s) of interest. Using commercially available 
software, such as ImageJ (Rasband, WS, ImageJ; National Institutes of Health, 
Bethesda, MD, http://rsb.info.nih.gov/ij), the detected bands can be relatively 
quantified. In Paper I WB was used to evaluate the specificity of in-house generated 
monoclonal anti-Ng antibodies and in Paper IV to relatively quantify full-length Ng in 
brain tissue. 
3.5 STATISTICS 
Statistical analyses were performed using GraphPad Prism for Windows software 
(GraphPad Software, La Jolla, CA, USA), SPSS (IBM SPSS Statistics for Windows, 
Armonk, NY: IBM Corp.) and R programming language (R Core Team (2013). R: A 
language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. http://www.R-project.org/).  Because biomarker values 
were skewed, non-parametric tests were used; Mann-Whitney U-test was used when 
comparing two groups or Kruskal-Wallis test when comparing three or more groups 
with post-hoc pairwise comparisons when appropriate. Associations between 
biomarker values were determined using Spearman’s rank correlation. All tests were 
two-sided with a significance level set to p  ≤ 0.05. p values for each family of 
comparisons were adjusted for multiple comparisons using Holm’s method to control 
the family-wise error rate. Graphs were created using GraphPad Prism. 
3.6 LIQUID CHROMATOGRAPHY AND MASS 
SPECTROMETRY 
Proteomics is a research field often associated with the identification of new 
biomarkers. In short, proteomics is the study of the proteome, which refers to the entire 
set of proteins that is expressed by a cell, a tissue or an entire organism262. There are 
many methods that can be applied in proteomics, and they are generally based on a 
sample preparation step, in order to reduce the complexity of the sample prior to MS 
analysis. MS is extremely useful as it allows for the identification of proteins and 
peptides in a biological sample. However, biological samples such as CSF are very 
complex, containing a multitude of proteins, salts, and cell debris, sometimes referred 
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to as interfering matrix components, which can interfere with sample analysis thus 
making identification difficult263. For example, the difference in concentration 
between high and low abundant proteins in plasma is up to ten orders of magnitude264. 
Sample clean-up and preparation is therefore important and sometimes even necessary. 
However, each pre-analytical step might also cause losses of the protein of interest, in 
addition to the risk of introducing contaminants, which may compromise the MS 
analysis. Many sample clean-ups and preparations utilise separation of the analytes 
based on size or biochemical properties in order to decrease the complexity and total 
protein concentration of the sample. One of the most used methods in today’s 
proteomics is liquid chromatography (LC) combined with MS (LC-MS) as it takes 
advantage of the separation abilities of LC together with the very sensitive mass 
analysis capabilities of MS. The principle of MS is that molecules are transferred from 
a solid or liquid state into gas phase, ionised, and separated based on their mass/charge 
(m/z). There are many different ionisation techniques, two of the most common ones 
are matrix-assisted laser desorption/ionisation (MALDI) and electrospray ionisation 
(ESI), both of which are soft ionisation techniques meaning that there will be relatively 
little degradation or fragmentation of the analyte. MS can be used to determine the aa 
sequence which is accomplished by tandem MS, often called MS/MS (mass 
selection/mass separation). MS/MS can also be employed to identify PTMs. PTMs are 
chemical alterations to proteins occurring after protein synthesis is finished and more 
than 300 kinds of PTMs have been discovered265. PTMs can alter protein function, and 
some PTMs can also be reversible, a common example being phosphorylation in signal 
transduction pathways266. Identification of PTMs and understanding their impact on 
protein function is therefore very important. Although MS is a very useful tool for 
identification of PTMs on proteins, analysis and correct identification can be very 
complicated265. In Paper IV, PTMs that had not previously been described on human 
Ng were characterised and identified using MS. Depending on the aim and 
methodology, MS can be used for both identification and quantification267. In Papers 
I, II, and IV, HI-MS using both nano-LC-MS and matrix-assisted laser 
desorption/ionisation-time-of-flight (MALDI-TOF) was used. 
3.6.1 LIQUID CHROMATOGRAPHY 
A chromatographic system consists of a stationary phase through which the sample is 
carried by a mobile phase. LC separates molecular species according to their 
physicochemical properties, e.g. hydrophobicity, charge, isoelectric point etc., using 
liquid as the mobile phase and a stationary phase. The stationary phase is a column 
packed with either monolithic material or silica beads onto which carbon chains of 
different lengths (C4, C8, C18 etc.) can be attached. Sample molecules that interact 
strongly with the stationary phase will have a longer retention time from the LC system 
while those that do not interact very strongly will elute faster. The system used in this 
work was mainly reversed-phase chromatography utilising a non-polar stationary 
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phase and a polar liquid phase. Here, analytes were separated based on their 
hydrophobicity through interactions with carbon chains (C18) inside the column and 
were eluted from the stationary phase by an increasing gradient of organic solvent, in 
this case, acetonitrile (ACN), in the mobile phase268. In order to obtain higher 
resolution and faster analyses, high-performance (previously high-pressure) liquid 
chromatography (HPLC) was utilised. In HPLC, the column packing material is 
smaller and more uniform in size combined with increased flow pressure compared to 
conventional LC at low pressure. LC can be performed either online, i.e. with the LC 
system connected directly to the mass spectrometer, or offline269. 
3.6.2 IONISATION TECHNIQUES 
3.6.2.1 Matrix-Assisted Laser Desorption/Ionisation 
In MALDI, the analyte is directly embedded in a matrix in crystallized form consisting 
of a light absorbing low molecular mass molecule269 on a target plate270. Important 
features of matrices are the capability to absorb the appropriate wavelength, rapid 
transition into gas phase, and the ability to ionise embedded analyte molecules without 
too much heating269. One of the most common matrices for analysis of smaller proteins 
and peptides is α-Cyano-4-hydroxycinnamic acid271. The molecules of the 
matrix/analyte mixture are evaporated into gas phase by a laser pulse from which the 
matrix absorbs light energy, resulting in excitation and ionisation of a fraction of the 
analyte molecules. One advantage of using MALDI is that it is quite tolerant to sample 
contamination. However, a complex sample such as CSF needs to go through some 
type of sample clean-up or enrichment, as analysis otherwise most likely only will 
detect the most abundant proteins or suffer from too high salt content. MALDI is most 
commonly combined with a TOF mass analyser272. 
3.6.2.2 Electrospray Ionisation 
In ESI, the sample is dissolved in a polar, volatile solvent and passed through a needle 
which is placed at high electric potential relative to the inlet of the mass spectrometer. 
The high difference in potential causes the fluid to form a so-called Taylor cone, 
causing a spray of charged droplets. As the sample droplets approach the heated inlet, 
they will evaporate and enter the spectrometer as gaseous ions. However, it is not 
entirely known how ions are formed during this process273-275. In ESI, the sample needs 
to be dissolved in a mixture of water and organic solvent. ESI can be run in negative 
or positive ionisation mode, and to aid in the formation of positive ions formic acid 
(FA) can be added while ammonia is often added to help form negatively charged ions. 
ESI is less tolerant to contaminants than MALDI and often requires separation of the 
proteins/peptides in the sample. However, ESI is readily combined with on-line LC in 
order to separate the analytes based on their chemical properties, thus reducing the 
complexity at a given acquisition time point, which in the end increases the overall 
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sensitivity and specificity of the MS analysis. ESI ions are especially favourable for 
fragmentation using collision-induced dissociation (CID) in which molecular ions are 
fragmented by collision with inert gas atoms or molecules for MS/MS analysis. Higher 
flow rates between 1 and 1000 µL / min are used in conventional ESI-MS, but lower 
flow rates between 20 and 300 nL / min can be used in nano-ESI. The advantages of 
nano-ESI compared to conventional ESI are lower sample consumption, significantly 
higher sensitivity as well as higher tolerance to salt272. 
3.6.3 MASS ANALYSERS 
3.6.3.1 Time of Flight 
In TOF, the molecular m/z’s of the analytes are calculated from their time of flight. 
Ions are accelerated in an electrical field, and all ions with the same charge will obtain 
the same kinetic energy, but their velocity is mass-dependent, meaning that heavier 
ions will have lower velocity compared to lighter ions. A double-charged (2+) ion will 
have a greater velocity compared to the corresponding single-charged (1+) ion. The 
analytes will travel from the target plate through a drift region where they will be 
separated based on their velocity towards a detector, and the difference in time between 
the starting pulse and when the ions hit the detector is the time of flight (tTOF). TOF 
requires a well-defined starting signal which makes MALDI and TOF a very good 
match since the MALDI laser pulse can be used as a starting point for the time 
measurement. TOF can be used in two modes; linear and reflector mode. When using 
linear mode, ions with identical m/z will, due to a small initial velocity spread, arrive 
at the detector at slightly different time points which will result in broader peaks in the 
mass spectrum subsequently limiting the resolution and thereby mass accuracy. In 
order to reduce the spread, a reflector is used as an energy focusing device through de- 
and re-acceleration of the ions in a strong electrical field which will give differentiated 
flight paths thus compensating for the initial spread in velocity272. TOF can also be 
used for identification of proteins and peptides by TOF tandem mass spectrometry 
(TOF/TOF), for details see Westman-Brinkmalm and Brinkmalm276. In Papers I, II, 
and IV MALDI-TOF/TOF was employed to identify multiple endogenous Ng peptides 
in CSF, plasma, and brain tissue. MALDI-TOF was used to detect and relatively 
quantify several Ng peptides in several cohorts included in Papers I, II, and IV. 
3.6.3.2 Quadrupole 
The quadrupole consists of four parallel rods in a symmetrical configuration. The rods 
have superimposed direct current (DC) and radio frequency (RF) potentials. Opposing 
rods are electrically connected pairwise with the potential of the other pair having the 
opposite sign. The potentials can be applied so that only ions within a desired m/z 
range will have a stable trajectory allowing them to travel through the entire 
quadrupole. The quadrupole allows for very high sensitivity when operated as a mass 
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filter, i.e. monitoring a fixed m/z. When analysing a broader m/z range, it has to be 
operated in scanning mode which will significantly decrease sensitivity272. 
Quadrupoles are commonly used in hybrid instruments where it often functions as a 
mass filter to select precursor ions272. 
3.6.3.3 Orbitrap 
The most recently developed mass analyser is the orbitrap. It utilises an electric field 
in order to trap ions in an orbital motion. The orbitrap consists of two electrodes; a 
symmetrical, barrel-shaped outer electrode which surrounds the inner electrode. The 
injected ions are trapped in a circular motion around the inner electrode. At the same 
time, they are also trapped in an oscillatory motion along the inner electrode axis in a 
manner that is dependent on their m/z. Contrary to the case in, for example, TOF-MS, 
the detection in the orbitrap is achieved by means of image current detection of the 
oscillating ions272. Hybrid instruments combining the orbitrap with a linear ion trap or 
a quadrupole have become popular today as they provide both high mass accuracy, 
high resolution, and high sensitivity272. In Papers I, II, and IV the hybrid instrument Q 
Exactive from Thermo Fisher Scientific was used as a high-resolution instrument in 
order to maximise the identification of Ng peptides as well as identifying PTMs on 
full-length Ng in Paper IV. The Q Exactive consists of a quadrupole mass filter, the 
orbitrap, and a higher-energy collisional dissociation (HCD, a variant of CID) cell, 
where precursor ions are fragmented by collision with N2 gas molecules for MS/MS277. 
3.6.4 DATABASE SEARCHES 
MS allows for determining the aa sequence of proteins and peptides present in a 
sample, and that information can, in turn, be used to identify the protein. However, as 
the human proteome consists of roughly 20,000 proteins, it is not feasible to identify 
the protein or peptide manually. The sequence, i.e. primary structure, is known for all 
human proteins, thus allowing for searching against a database containing all 
sequences. The most common method that database searches are based on today is 
MS/MS spectra derived from individual peptides from an enzymatically digested 
protein. It is also possible to use databases to search for endogenous peptides, i.e. 
peptides that are not created from protein digestion during sample preparation but that 
are naturally present in the biological sample. There are a number of software available 
which are based on different algorithms278. Most software also allows for identification 
of PTMs as well. In Papers I, II, and IV all database searches were performed using 
MS/MS data from endogenous Ng species. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
As synaptic pathology is an early event in AD and also correlates better with cognitive 
decline compared to AD neuropathology100, 102, 103, synaptic proteins are candidates for 
new biomarkers of AD. The postsynaptic protein Ng has in mouse models been shown 
to be important in the formation and storage of long-term memories through LTP246, 
247. In addition, by using semi-quantitative WB, it was previously shown that the CSF 
levels of Ng are increased in AD compared to controls108. 
In order to study Ng in detail, three monoclonal Ng antibodies were developed; Ng2, 
Ng3, and Ng7. These, along with the commercially available polyclonal antibody 
ab23570 (Upstate), were shown to detect both recombinant and endogenous full-length 
Ng using WB, HI-MS, and direct ELISA. Ng2, Ng3 and Ng7 were epitope mapped, 
using a series of short overlapping peptides in ELISA and HI-MS. All three antibodies 
were found to bind the C-terminal region of Ng with Ng2 recognising aa 52-63, Ng3 
recognising aa 54-65, and Ng7 recognising aa 52-65 (Figure 4). In the HI-MS 
experiments, a combination of Ng2 and Ng3 was used as this combination yielded the 
best signal-to-noise using MALDI-TOF. In order to relatively quantify Ng peptides in 
clinical samples, a known concentration of an internal standard, consisting of a heavy 
isotope-labelled version of Ng43-75, was added to all samples. A sandwich ELISA 
using Ng7 for capture and Upstate for detection was also developed. 
Figure 4. Epitope mapping of in-house generated anti-neurogranin antibodies. The 
antibody Ng2 reacted with the peptide Ng52-63, Ng3 reacted with Ng54-65, and Ng7 
reacted with both of these peptides. 
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Using HI-MS, we showed that Ng is present as several endogenous peptides in both 
CSF (Figure 5) and brain tissue, and that full-length Ng is readily detectable in brain 
tissue, but not CSF, and that it is most likely subjected to PTMs. In total, 15 
endogenous Ng peptides were identified in CSF and nine in brain tissue, of which 
several were present in both. The major peaks corresponded to Ng43-75 and Ng44-75 
in CSF (Figure 5), and Ng48-76 in brain tissue. Most of the identified peptides ended 
at aa 75, 76 or 78 in both CSF (Figure 5) and brain tissue. 
Figure 5. MALDI-TOF spectrum displaying several C-terminal neurogranin 
peptides in cerebrospinal fluid. Ng48-76, which is marked by a star, was significantly 
increased in sAD compared to controls in two separate cohorts in this paper. Ng43-
75* represents the heavy isotope-labelled peptide that was used as an internal 
standard during quantification. 
In order to evaluate CSF Ng as a potential novel biomarker for AD, Ng was quantified 
using both ELISA and HI-MS in a pilot study of CSF from 16 sAD patients and 10 
healthy controls. HI-MS analysis of C-terminal peptides showed that Ng48-76 was 
significantly increased in sAD CSF compared to controls (p = 0.002) and that several 
other peptides had a trend towards increased concentrations in sAD but failed to reach 
statistical significance. ELISA showed similar results with increased CSF Ng 
concentrations in sAD compared to controls, p < 0.0001 (Figure 6A). A second study 
on CSF from 44 sAD patients and 30 controls was analysed, and increased CSF Ng in 
sAD compared to controls was confirmed by both ELISA (p < 0.001) (Figure 6B) and 
HI-MS (Ng48-76, p < 0.05). The ELISA and HI-MS results showed a significant 
correlation in both study 1 (rs = 0.88, p < 0.0001) and study 2 (rs = 0.70, p < 0.0001). 
A third independent study included 40 individuals each of sAD, MCI, and healthy 
controls. This cohort was aimed to verify the results of the two pilot studies as well as 
testing the performance of CSF Ng in the early stages of sAD and was analysed only 
by ELISA due to the large volume needed for HI-MS analysis (1 mL). The MCI 
patients were followed between 2 and 4 years. The analysis showed that CSF Ng was 
increased in sAD compared to controls (p < 0.001) also in this cohort. Furthermore, 
when the MCI group was divided into stable MCI (sMCI) and MCI progressing to 
dementia due to sAD (MCI-AD), MCI-AD had significantly increased CSF Ng 
compared to both controls (p < 0.001) and sMCI (p < 0.001) while sMCI had lower 
CSF Ng compared to sAD (p < 0.05). There was no difference between controls and 
sMCI, or MCI-AD and sAD (Figure 6C). 
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Figure 6. Scatter plots displaying cerebrospinal fluid neurogranin concentrations 
quantified by ELISA from (A) Study 1 (B) Study 2 (C) Study 3. Data presented are 
median and interquartile ranges. 
The concordance between biomarker positive for Aβ1-42 and Ng, defined as <634 
pg/mL and >237 pg/mL respectively, was 75%. Cox proportional hazard models were 
used to assess the capability of CSF Ng to predict conversion from MCI due to sAD 
and dichotomised CSF Ng concentrations of 152 pg/mL predicted conversion with a 
hazard ratio of 12.8, thus indicating an increased risk of conversion to AD. Although 
CSF Ng was not associated with MMSE at baseline, there was a high association with 
annual decline in MMSE (p = 0.001). Both t-tau (rs = 0.70, p < 0.0001) and p-tau (rs = 
0.61, p < 0.0001), but not Aβ1-42, were strongly correlated with CSF Ng, especially in 
sAD and MCI but also in controls. 
In this paper, we showed for the first time that Ng is present as multiple endogenous 
peptides in both CSF and brain tissue, some of which were found in both. Furthermore, 
the data also show that full-length Ng in brain tissue most likely has several PTMs 
present but that concentrations of full-length Ng in CSF probably are very low 
compared to brain tissue. We found that CSF Ng is markedly increased in both sAD 
and MCI compared to controls and that CSF Ng, as measured by ELISA, was 
associated with CSF tau as well as decline in MMSE. These results suggest that CSF 
Ng reflects cortical synaptic degeneration as defined by CSF increase of tau and that 
CSF Ng is a prognostic biomarker for cognitive decline. As the antibodies used for HI-
MS both had epitopes in the C-terminal region, no N-terminal peptides were found. 
Future studies using antibodies with epitopes near the N-terminal or mid-region are 
needed to elucidate if N-terminal fragments are also present in brain tissue and CSF. 
Just as the specific peptide Aβ1-42 is a biomarker for AD, Ng48-76 was increased in 
sAD in two separate cohorts. Such an increase could indicate that it may be useful to 
monitor specific Ng peptides rather than, or perhaps as a complement to, ELISA which 
most likely detects many different peptide species, even though the two methods 
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correlated well. Since Ng48-76 was the dominating peptide in brain tissue as well as 
significantly increased in sAD CSF, our data indicate that this specific peptide is 
closely related to AD pathology.  
The most important findings in Paper I were that CSF Ng is increased in sAD and MCI 
due to AD, and that the specific peptide Ng48-76 is increased in sAD CSF. 
4.2 PAPER II 
Although Ng is considered to be a neuron-specific protein, it is also expressed in the 
periphery by platelets and a couple of other cell types and tissues239. Since blood is 
much easier to access compared to CSF, blood-based biomarkers are highly sought 
after. Therefore, the aim was to characterise Ng in plasma and investigate if plasma 
Ng could be used as a biomarker for AD, as well as to compare peripheral Ng with Ng 
originating from the CNS, i.e. CSF and brain tissue. 
In this paper, an MSD immunoassay, based on Ng7 for capture and Upstate for 
detection, and HI-MS with Ng2 and Ng3 were used for analysis. 
Using HI-MS, plasma Ng was characterised and 16 endogenous Ng peptides were 
identified, most ending at aa 75 and 78, of which seven had not been detected in CSF 
or brain tissue previously. The most abundant peptides were Ng43-75 and Ng44-75 
(Figure 7). Full-length Ng was also present in plasma and was most likely altered by 
PTMs.  
Figure 7. MALDI-TOF spectra displaying several C-terminal neurogranin peptides 
in cerebrospinal fluid and plasma. In plasma, none of the detected peptides differed 
significantly between sAD and controls. Ng43-75* represents the heavy isotope-
labelled peptide that was used as an internal standard during quantification. Ng48-76, 
which is marked by a star, was found to be increased in sAD CSF in Paper I. ¤ signifies 
peptides that were only found in plasma. † denotes peaks caused by non-specific 
binding of other plasma proteins to the magnetic beads used in HI-MS. 
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A cohort of paired plasma and CSF samples from 25 sAD individuals and 20 healthy 
controls was analysed by both HI-MS and MSD (plasma samples) or only MSD (CSF 
samples). In the HI-MS analysis, several Ng peptides were relatively quantified in 
plasma, but none were found to be significantly different between the groups. MSD 
analysis showed similar results. A second validation study of plasma samples analysed 
by HI-MS also failed to identify any significant difference between the groups for any 
of the detected peptides. However, MSD analysis of the paired CSF samples showed 
a marked increase of Ng in sAD compared to controls (p < 0.0001). There was no 
correlation between plasma and CSF Ng. In the paired plasma and CSF cohort the 
controls were significantly younger than the sAD group, but there was no association 
between Ng and age. 
The stability of CSF Ng during storage was evaluated by MSD analysis of CSF kept 
at room temperature, +4 °C, or −20 °C for between 1 and 7 days. At both +4 °C and 
−20 °C Ng concentrations were not significantly altered during 7 days. When stored at 
room temperature for 2 days, the CSF Ng concentrations did not change. However, 
after day two there was a 30% drop in concentration. To address the question of 
whether any degradation of full-length Ng is taking place in CSF and plasma, multiple 
plasma and CSF samples were depleted of all detectable native Ng by three 
consecutive IPs before recombinant full-length Ng was added. After a 24h incubation 
at room temperature, the samples were analysed by HI-MS in order to screen for 
degradation products in the form of newly formed peptides. In CSF, there was no de 
novo formation of Ng peptides, while in plasma, 14 Ng peptides were detected after 
the incubation. 
In this paper, we showed for the first time that Ng is present in plasma as both modified 
full-length protein and many endogenous peptides. Seven of the identified peptides 
have only been detected in plasma and not in CSF or brain tissue (see Paper I), and 
thus seems to be specific for the plasma Ng profile. We also found that recombinant 
full-length Ng was degraded into 14 peptides in plasma. These proteolytic peptides are 
most likely formed by some of the proteases present in plasma. Some of the de novo 
peptides corresponded to naturally occurring Ng peptides in plasma and CSF, while 
four did not have any previously identified native counterparts. 
It is of particular worth to note that Ng48-76, which was identified as increased in sAD 
CSF in Paper I, was not naturally present nor produced upon incubation of recombinant 
full-length Ng in plasma. It is therefore unlikely that the enzyme(s) responsible for 
these specific cleavages (both at the N- and C-terminus) are present or active in plasma, 
at least under the conditions of the experiments. Since there are several peptides ending 
at aa 76 present in both brain tissue and CSF, but not plasma, and this particular 
cleavage does not seem to occur in the periphery, the data points towards two separate 
pools of Ng with very little to no exchange between them; a CNS pool consisting of 
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the species found in CSF and brain tissue and a peripheral pool, i.e. plasma and perhaps 
other tissues as well. This scenario is further supported by the fact that the cluster of 
peaks representing full-length Ng with PTMs looked distinctly different in plasma 
compared to brain tissue. 
The key findings in Paper II were that full-length Ng is not degraded into peptides in 
CSF and that there are no native or de novo formed Ng peptides in plasma that ends at 
aa 76. This is of great importance because it suggests that CSF Ng, and in particular 
Ng48-76, reflects the active neurodegenerative processes of the brain in AD. In 
conclusion, CSF Ng might be a novel clinically accessible biomarker for synaptic 
function in sAD. However, this hypothesis needs to be thoroughly investigated in 
future studies.  
4.3 PAPER III 
Others have previously shown that increased CSF Ng seems to be specific for AD279-
282. However, these studies have been fairly small and did not include a definitive 
neuropathological diagnosis. In this paper, the aim was to investigate if elevated CSF 
Ng is specific to AD by quantifying Ng in CSF from seven other neurodegenerative 
disorders, including cases with definitive neuropathological diagnosis, in order to test 
the hypothesis that increased CSF Ng is specific for AD.  
We developed and optimised an ELISA based on the in-house generated monoclonal 
antibodies Ng2 and Ng22 (epitope aa 63-75). The study included CSF from a total of 
915 subjects including 75 healthy controls, 114 MCI, 397 sAD, 6 PCA, 96 FTD (of 
which 46 bvFTD, 12 lvPPA, 20 nfvPPA, 18 svPPA), 68 ALS, 37 PD without dementia, 
19 PD with MCI (PD MCI), 29 PD with dementia (PDD), 33 DLB, 21 CBS, and 20 
PSP patients. 116 of all subjects had a definitive diagnosis by neuropathological 
examination and included 75 sAD, 16 DLB, 12 FTD, 7 ALS, and 6 PSP subjects. 
ELISA analysis of sAD, MCI, and controls showed that CSF Ng was significantly 
increased in sAD compared to controls (p = 0.0001) as well as MCI (p < 0.0001). 
Moreover, when each group was split into AD biomarker-positive or negative, 
biomarker-positive defined as t-tau > 93 pg/mL and Aβ1-42 < 192 pg/mL and 
biomarker-negative as the opposite, biomarker-positive individuals had significantly 
higher CSF Ng concentrations compared to biomarker-negative for both controls (p = 
0.03), sAD (p < 0.0001), and MCI (p < 0.0001). Also AD biomarker-positive DLB 
subjects had increased CSF Ng compared to biomarker-negative DLB (p = 0.0005) 
and sAD (p = 0.002). Biomarker-negative subjects from the sAD (n=83) and MCI 
(n=74) groups as well as biomarker-positive controls (n=9) were excluded from further 
analysis. 
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When comparing CSF Ng concentrations of sAD with the other neurodegenerative 
diseases, sAD had significantly increased concentrations compared to PD (p < 0.0001), 
PD MCI (p = 0.005), PDD (p < 0.0001), DLB (p = 0.002), CBS (p = 0.03), PSP 
(p = 0.004), FTD (p < 0.0001), and ALS (p < 0.0001), but not PCA (Figure 8). There 
were no differences in CSF Ng concentrations between any of the other groups. When 
FTD was split into clinical subgroups, sAD had increased concentrations of CSF Ng 
compared to nfvPPA (p = 0.0004), svPPA (p = 0.01), and bvFTD (p < 0.0001), but not 
lvPPA. In contrast, lvPPA concentrations of CSF Ng were similar to those of sAD and 
were in fact higher compared to bvFTD (p = 0.02). 
Figure 8. Scatterplot displaying cerebrospinal fluid concentrations in biomarker-
positive Alzheimer’s disease compared to seven other neurodegenerative diseases. 
The data presented are median with interquartile ranges. The line represents the 
median CSF Ng concentration of the healthy control group. 
By using a biomarker index model, we tested if CSF Ng could be used in order to 
distinguish between different neurodegenerative disorders. When Ng was added to the 
model, this led to an increase in accuracy in distinguishing between controls and 
bvFTD (24%), MCI vs. bvFTD (3.6%), and PD vs. bvFTD (9.5%). By including Ng, 
there was also an increase in accuracy in distinguishing between MCI and PD (7.7%), 
MCI vs. PD MCI (6.4%), and MCI vs. PDD (4.3%). 
There were strong correlations between both t-tau and p-tau with CSF Ng in several of 
the groups (Table 1), but no associations were found between Aβ1-42 and CSF Ng. 
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Throughout all subjects included in the study, there was a significant correlation 
between Ng and longitudinal decline in MMSE scores per year (rs=0.17, p = 0.001). 
However, when dividing all subjects into groups, the only significant relationship was 
in the MCI group (rs = 0.45, p = 0.001). 
 
 
 
 
 
 
 
 
 
 
Table 1. Correlations between CSF Ng and tau. The values are Spearman’s rank 
coefficient. *p < 0.05, **p < 0.01, ***p < 0.001 
In order to investigate the association between CSF Ng and APOE ε4, all subjects were 
divided into three groups based on the number of ε4 alleles, i.e. zero, one, or two 
copies. There was a gene dose-dependent increase in CSF Ng with individuals that had 
two copies of the ε4 allele having the highest concentrations. There were significantly 
higher concentrations of CSF Ng in this group compared to subjects with both one (p 
= 0.02) and no (p < 0.0001) ε4 allele. There was also a significant difference between 
the groups with one or no ε4 allele (p < 0.0001). When grouping clinically diagnosed 
sAD subjects according to ε4 status, individuals with no copies had lower CSF Ng 
compared to sAD patients with one (p = 0.007) and two (p = 0.002) ε4 alleles. 
When looking at the cases confirmed by neuropathology, CSF Ng was increased in 
sAD compared to ALS (p = 0.03), FTLD (p = 0.006), and DLB (p = 0.03), but not PSP. 
Upon dividing the sAD subjects into four groups according to the severity of 
pathological changes as measured by CERAD (neuritic Aβ plaques) and Braak staging 
Clinical diagnosis t-tau p-tau 
Control 0.61*** 0.39*** 
sAD 0.77*** 0.56*** 
MCI 0.79*** 0.60*** 
PD 0.75*** 0.14 
PD MCI 0.51* 0.52* 
PDD 0.48** 0.18 
PCA 0.3 − 0.3 
DLB 0.77*** 0.56** 
CBS 0.87*** 0.2 
PSP 0.37 − 0.26 
ALS 0.48*** − 0.097 
bvFTD 0.57*** 0.49** 
lvPPA 0.64 0.33 
nfvPPA 0.76** 0.19 
svPPA 0.80** 0.35 
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(spread of NFTs), from no AD to high-level AD pathology, we found that CSF Ng 
increased with the degree of pathological changes. For both Braak stages and CERAD 
scores, there was a clear trend of increasing CSF Ng concentrations with an increased 
degree of AD pathology. However, the only significant differences were between the 
high-level AD pathology and the no AD pathology groups (p = 0.0007 and p = 0.0002 
for Braak stages and CERAD scores respectively) and moderate vs. no AD pathology 
for Braak stage (p = 0.02). Furthermore, CSF Ng concentrations were positively 
associated with plaque load in both the amygdala (p < 0.0001) and hippocampus (p = 
0.0006) as well as neuronal loss in the hippocampus (p = 0.04). When examining the 
relationship between CSF Ng and the different components of the ABC score, i.e. Thal 
stage, Braak stage, and CERAD score, stages 0 and 3 (p = 0.0003), and stages 1 and 3 
(p = 0.02) in Thal staging had significantly different concentrations of CSF Ng. 
Moreover, Braak stage 3 had significantly higher CSF Ng compares to stages 0 (p < 
0.0001) and 1 (p = 0.002). Lastly, there was a significant difference between CERAD 
score 0 and 3 (p < 0.0001). 
In this paper, we showed that sAD have significantly increased concentrations of CSF 
Ng compared to six of the seven other investigated major neurodegenerative diseases, 
with the exception of PCA, and lvPPA when dividing FTD subjects into clinical 
subgroups. These results could be explained by the fact that both PCA and the majority 
of lvPPA cases have AD neuropathology. Furthermore, not only was increased CSF 
Ng specific for sAD across clinically diagnosed cases, but it was also increased in 
autopsy-confirmed cases which is important because of the relatively common 
occurrence of neuropathological comorbidity. The results also showed that addition of 
CSF Ng into the biomarker profile of AD would be useful since it decreased the 
probability of misdiagnosing bvFTD as healthy control or MCI, which would be likely 
to have a negative impact on study results. 
CSF Ng concentrations increased in sAD subjects with one or two copies of the APOE 
ε4 allele, and a similar trend was found in MCI. As homozygous ε4 carriers have been 
found to have an increased plaque load, our results might be linked to increased 
synaptic damage due to plaques. When an association between AD pathology and CSF 
Ng was investigated, the results did indeed show a strong correlation between plaque 
load and CSF Ng in both the hippocampus and amygdala. Furthermore, both plaque 
and NFT spreading were significantly correlated with CSF Ng thus indicating a close 
relationship between Ng and the major aspects of AD neuropathology. A direct link 
between CSF Ng and synaptic function was also found since CSF Ng was associated 
with the rate of cognitive decline. 
The key findings in Paper III were that CSF Ng is specific for sAD compared to most 
other major neurodegenerative diseases and that CSF Ng correlated very well with 
multiple aspects of AD neuropathology, including neuronal loss. 
 42 
 
4.4 PAPER IV 
Here, the aim was to perform a more thorough characterisation of Ng in brain tissue as 
well as quantify both full-length and endogenous Ng peptides in post-mortem brain 
tissue. Ng was quantified in sAD, fAD, healthy controls, and CU-AP subjects. The 
CU-AP individuals have both plaques and tangles, but without any cognitive deficits, 
which makes them very interesting to compare with the other groups.  
We generated a new antibody towards Ng, Ng36, which was raised against aa 63-75 
and developed a new sandwich ELISA using Ng36 as capture antibody and Ng2 as 
detection antibody. Ng36 was characterised by HI-MS and found to detect the same 
peptides, as well as full-length Ng, in human brain tissue as Ng2 and Ng3. 
Endogenous Ng was characterised using HI-MS with Ng2 and Ng3. In total, 39 
endogenous peptides were identified by high-resolution LC-MS/MS, and most of them 
ended at aa 75, 76, or 78 and started between aa 42 and 54 in a step-wise manner 
(Figure 9). In addition, 15 of these endogenous peptides were also identified with 
MALDI-TOF/TOF (Figure 10A). 
Figure 9. Endogenous neurogranin peptides in brain tissue identified using HI-
MS. 
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Figure 10. MALDI-TOF spectra of neurogranin in brain tissue. (A) MALDI 
spectrum displaying several endogenous C-terminal neurogranin peptides. (B) 
MALDI spectrum displaying a cluster of peaks representing full-length neurogranin 
with different sets of PTMs. Ng43-75* represents the heavy isotope-labelled peptide 
that was used as an internal standard during quantification. Ng48-76, which is marked 
by a star, was found to be significantly increased in sAD CSF in Paper I. † signifies 
peptides with identical mass that can therefore not be distinguished during MALDI-
TOF analysis. 
The PTMs glutathione (GSH), phosphorylation, disulfide bridge, cysteinyl, 
acetylation, and oxidation were also identified on full-length Ng (Figure 10B). 
Interestingly, the placement of the PTMs affected retention time during nano-LC-MS. 
Full-length and peptide Ng were relatively quantified using HI-MS in a pilot study on 
superior parietal gyrus of 10 sAD subjects and 10 healthy controls. In this study, 14 
endogenous peptides, as well as all species of full-length Ng, were quantified in all 
samples. After analysing the ratio between each of the peptides and the sum of all full-
length Ng species, i.e. total full-length Ng, we found that eight peptide-to-total full-
length Ng ratios were significantly increased in sAD compared to controls (p < 0.05 
for all ratios), thus signifying decreased concentrations of full-length Ng compared to 
these peptides. 
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A second study, including temporal cortex from 9 sAD, 10 fAD, 13 CU-AP, and 9 
controls, was analysed by HI-MS in order to validate the results from the pilot cohort. 
Ten endogenous Ng peptides, as well as all species of full-length Ng, were quantified 
in all samples of the second cohort. Here, nine of the quantified peptides showed 
significant differences across groups in peptide-to-total full-length Ng ratios. The most 
pronounced difference was seen in Ng53-78, for which the peptide-to-total full-length 
ratio was significantly reduced in sAD and fAD compared to controls (p = 0.004 for 
sAD; p = 0.0005 for fAD), and compared to CU-AP (p = 0.007 for sAD; p = 0.002 for 
fAD). When comparing the concentrations of total full-length Ng between the groups 
fAD had significantly lower levels than sAD (p = 0.03), CU-AP (p = 0.0003), and 
controls (p = 0.01). There was also a trend towards reduced total full-length Ng in sAD 
compared to controls and CU-AP, although it failed to reach statistical significance. 
Next, the second cohort was analysed by WB (antibody Ng36), which most likely 
quantifies full-length and nearly full-length Ng, and fAD had reduced levels compared 
to CU-AP (p = 0.008), and controls (p = 0.0002). Once again there was a trend, which 
failed to reach statistical significance, of lower levels in sAD compared to CU-AP and 
controls. The results from ELISA analysis were similar to WB, with significantly lower 
concentrations in fAD compared to CU-AP (p = 0.035), and controls (p = 0.003), and 
significantly lower concentrations in sAD compared to CU-AP (p = 0.017). While 
ELISA most likely detects Ng in both peptide and intact form, the peptides probably 
exit the gel in WB due to their small size, meaning that this method mainly quantifies 
full-length, or nearly full-length, Ng. 
In order to investigate any associations between brain Ng and degree of 
neuropathological changes, all subjects from the second cohort were divided according 
to the degree of neuropathological changes, as estimated by Braak stage (0-I, II-IV, V-
VI), Thal phase (0-1, 2-3, 4-5), and CERAD score (0, A, B, C) separately. We 
discovered that brain Ng, irrespective of the method of quantification, was 
significantly higher in individuals with moderate and high-levels of NFTs and plaque 
load (i.e. Braak stage and CERAD score). For Thal phase, i.e. spreading of plaques, 
only the peptide-to-total full-length ratio of Ng53-78 displayed a significant difference 
between low and moderate pathology. 
In this paper, full-length protein and endogenous Ng peptides were for the first time 
quantified in human brain tissue. In two independent cohorts, the ratios of peptide-to-
total full-length Ng were increased for several peptides in sAD compared to healthy 
controls, which indicate increased concentrations of these peptides compared to full-
length Ng. Moreover, in the second cohort, the ratios for several peptides were also 
increased in sAD compared to CU-AP and in fAD compared to both controls and CU-
AP. In other words, there seems to be a shift from full-length protein towards peptides 
in both forms of AD. The results from WB and ELISA also supports this theory, as 
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fAD had decreased concentrations compared to both controls and CU-AP in those 
analyses and there was a trend of lower concentrations for sAD compared to controls 
and CU-AP as well. As previously mentioned, WB most likely detects mainly full-
length Ng, while the ELISA most likely quantifies a mixture of both peptides and full-
length Ng. However, the concentrations of the peptides were fairly low compared to 
the full-length Ng species, which probably is why the ELISA results were similar to 
WB. Thus, all three methods point to full-length Ng being decreased in both sAD and 
fAD. Although calpain-1 and prolyl endopeptidase were recently shown to be capable 
of cleaving Ng in vitro to generate several Ng peptides283, further studies are needed 
since the reported cleavages do not account for all the peptides identified here. 
Results from Paper III showed that CSF Ng quantified by ELISA is strongly correlated 
with the degree of neuropathological changes, which here was confirmed for brain Ng 
as well. As CERAD scores were more strongly associated with Ng than Thal phases, 
it seems that Ng is more closely associated with the number of plaques rather than the 
degree of spreading. 
Strikingly, the CU-AP group did not have increased peptide-to-total full-length Ng 
ratios but were rather very similar to healthy controls, even though most subjects had 
a moderate degree of both plaques and NFTs. This indicates that the CU-AP 
individuals might have some mechanism that is either capable of protecting synapses 
from the damage normally induced by the pathological changes, or that synaptic 
damage still occurs, but they are somehow able to compensate for it. 
We have previously shown that Ng is present in CSF as many different endogenous 
peptides (Paper I) and that there seems to be a CNS Ng pool comprised of CSF and 
brain tissue (Paper II). Since it was demonstrated here that full-length Ng most likely 
is degraded into peptides to a greater degree in sAD and fAD, it is tempting to speculate 
that the increased presence of peptides in sAD CSF presumably originates from the 
brain. Thus, CSF Ng is likely to mirror the ongoing synaptic degeneration in the brain.  
The most important findings in Paper IV were that Ng levels were strongly associated 
with the degree of neuropathological changes regardless of group and that there was a 
shift from full-length to peptide Ng in both sAD and fAD compared to controls and 
CU-AP. As this shift was not present in healthy controls or CU-AP individuals, of 
which the latter have both plaque and tangle pathology but no cognitive impairment, 
the results indicate that Ng is a biomarker for AD-related synaptic degeneration leading 
to cognitive decline.  
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5 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
The work presented in this thesis includes characterisation of Ng in the CNS and 
periphery as well as evaluation of Ng as a biomarker in AD. 
Using HI-MS, we were able to perform a detailed characterisation of both full-length 
Ng in brain tissue, where several PTMs were identified for the first time, and of 
endogenous Ng peptides that were present in CSF, plasma, and brain tissue. We 
showed that peptide profiles are distinctly different; some Ng peptides were 
ubiquitously present while others seemed to be associated with either the periphery or 
CNS, indicating the presence of two separate Ng pools with very little or no exchange 
between them. Most noticeably, many peptides ending at aa 76 were present in both 
brain tissue and CSF while no such peptides were detected in plasma (Figure 11). In 
addition, the endogenous peptide Ng48-76 was significantly increased in sAD CSF. 
Figure 11. MALDI-TOF spectra displaying C-terminal neurogranin peptides found 
in cerebrospinal fluid, brain tissue, and plasma. The peptide profiles of CSF and 
brain tissue were very similar compared to plasma, especially with consideration to 
peptides ending at aa 76. These peptides were abundant in both brain tissue and CSF, 
but no such peptides were identified in plasma. We therefore suggest that there are two 
separate Ng pools; the CNS pool consisting of brain tissue and CSF and the peripheral 
pool comprised of plasma. As the peptide profiles of the two pools are quite different, 
there appears to be very little or no exchange between them. Ng48-76, which is marked 
by a star, was found to be significantly increased in sAD CSF in Paper I. Ng43-75* 
represents the heavy isotope-labelled peptide that was used as an internal standard 
during quantification, but was not added in the brain tissue spectrum shown here. § 
and ¤ signify peptides that were found exclusively in brain tissue and plasma, 
respectively. † denotes peaks caused by non-specific binding of other plasma proteins 
to the magnetic beads used in HI-MS. 
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Taking these results into consideration, our data indicate that the processes leading to 
the formation of peptides ending at aa 76 are specific to the CNS and might reflect 
ongoing neurodegeneration in AD. Since investigation of the ratio between Ng 
peptides and full-length Ng revealed a shift from intact Ng towards peptides in both 
sAD and fAD, it seems that the degradation of full-length Ng somehow is connected 
to neurodegenerative processes in AD, but as of now it is not known if that connection 
is direct, or if it is more of a secondary effect. As mentioned, two enzymes that together 
are capable of generating some of the endogenous peptides have been discovered283, 
but more studies on the mechanisms behind the endogenous peptides might shed some 
light on the generation of peptides and the significance of increased peptides in terms 
of disease progress or stage. 
In order to get a better understanding of the neurodegenerative processes that might 
affect or influence the formation of Ng peptides, especially those ending at aa 76, one 
might consider performing a detailed peptide characterisation in both brain tissue and 
CSF of other neurodegenerative diseases, such as those included in Paper III, as well. 
Such studies might give insight to if the formation of certain peptides might be unique 
for AD and thus could be relevant for the neurodegenerative process. However, it 
should be noted that even though researchers have identified numerous endogenous 
peptides from Aβ and APP37, 60, 284, the physiological function is still unknown for the 
majority of these peptides. If a certain Ng peptide, or peptides, was found to have a 
role in disease development or reflect the progression of AD especially well, one might 
consider designing neo-specific antibodies towards this peptide in order to construct a 
new immunoassay, just as there are specific assays for Aβ1-38, Aβ1-40, and Aβ1-42. If 
such a specific immunoassay would be developed, and of course depending on what 
peptide that should be quantified, it might perhaps be possible to revisit plasma Ng. 
The difference in Ng concentration between plasma and CSF, both measured by MSD 
and HI-MS, appears to be quite big, meaning that if CNS-specific peptides possibly 
were present at very low concentrations, they would be very difficult to detect. 
Although we did not detect any CNS-specific peptides in plasma using HI-MS, it is 
not impossible that such a feat could be achieved with a highly sensitive neo-specific 
immunoassay, such as the Single Molecule Array (Simoa) technology285. Regarding 
the identified PTMs, more work is needed in order to find out what they mean and if 
they might have some effect on the function of Ng. 
CSF Ng measured by different immunoassays was increased in both sAD and MCI 
compared to controls. In fact, numerous independent studies have now shown 
increased CSF Ng in both sAD251-255 and MCI254, 255, 286 compared to healthy controls. 
A comparison of three assays for CSF Ng also showed very similar performance 
between them, even though they were all based on different antibodies and epitopes, 
indicating that CSF Ng has a robust performance as a biomarker282. One hypothesis 
that might explain the increase of Ng in CSF is that elevated concentrations of Ng 
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peptides in brain tissue might be reflected in CSF. Detailed HI-MS analysis of paired 
CSF and brain tissue samples from individuals with sAD and controls could perhaps 
shed some light on the possible connection between Ng in CSF and brain tissue. In 
addition, we also showed that increased CSF Ng is specific for sAD compared to a 
diverse set of other common neurodegenerative diseases. As already mentioned, other 
groups have also shown that CSF Ng is specific for sAD279-282, but never before in such 
a large material or using neuropathologically confirmed cases. Thus, the increase in 
CSF Ng for sAD and MCI suggests that CSF Ng is a useful biomarker for 
neurodegenerative processes that are specific for AD, even at early stages. The fact 
that Ng is specific for AD is very important as it means it may be used as inclusion, or 
exclusion, criteria in clinical trials as well as used for differential diagnosis in clinics. 
However, what CSF Ng actually reflects, and the exact reasons for why increased CSF 
Ng is specific for AD, remains to be identified. 
Considering that HI-MS analysis revealed that at least one Ng peptide, Ng48-76, is 
increased in sAD CSF and that peptide-to-total full-length Ng ratios were increased in 
both sAD and fAD brain tissue, it might be of interest to characterise the CSF Ng 
peptide profile of fAD using HI-MS as well. To our knowledge, no such papers have 
been published. However, immunoassay analysis indicates that CSF Ng also is 
increased in fAD279. It would also be very informative to follow fAD individuals 
longitudinally, with respect to CSF Ng levels, especially before the age of onset. Such 
studies are ongoing and may reveal how early CSF Ng starts to increase. 
The finding that Ng measured in both CSF and brain tissue correlated very well with 
the degree of neuropathological changes speaks for that Ng indeed reflects these 
changes. Both CSF and brain Ng were closely associated with tau, as a CSF biomarker 
as well as in the form of NFTs. In contrast, there was very little or no association 
between CSF Ng and Aβ1-42 while brain Ng correlated well with plaque load but not 
with degree of spreading. Therefore, it might be of interest to investigate both CSF and 
brain Ng in patients with primary tauopathies in order to gain further insights into the 
link between Ng and tau. 
What does analysis of CSF Ng contribute with compared to the core AD biomarkers 
alone? There are studies which have shown that including CSF Ng also increase 
diagnostic accuracy286 and, as shown in Paper III, it might decrease the risk of 
misdiagnosing bvFTD as healthy control or MCI. Furthermore, since we and others 
have shown that CSF Ng correlates well with both tau neuropathology and tau 
measured in CSF, it might be possible to use CSF Ng as a surrogate marker to monitor 
the effect of drugs targeting tau pathology. 
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Overall, larger studies and analysis of longitudinal samples, preferably from subjects 
who are followed for at least 5 years, are needed in order to investigate if CSF Ng 
indeed is capable of detecting pathological changes earlier than tau and Aβ1-42. Also, 
PET ligands against the synaptic protein SV2A, allowing for monitoring of synaptic 
density in living patients, are currently being developed and evaluated287, 288. It would 
therefore be of great interest to investigate how CSF Ng correlates with SV2A PET or 
other future PET ligands for synaptic proteins. 
In conclusion, the results from the papers included in this thesis have shown that CSF 
Ng is a novel biomarker for AD, even in early stages of the disease, and that CSF Ng 
can be used to differentiate between AD and other neurodegenerative diseases. Thus, 
Ng is indeed a new, and useful, item in the AD biomarker toolbox. 
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